RN 267891-24-7 CAPLUS
CN Benzamide, N-(5-chloro-2-pyrimidinyl)-2-[(4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)



RN 267891-25-8 CAPLUS
CN Benzamide, N-[1-[(1-bromo-3-isoquinolinyl)amino]-3-isoquinolinyl]-2-[(4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***
RN 267891-26-9 CAPLUS
CN Benzamide, 2-[(4-pyridinylmethyl)amino]-N-8-quinolinyl- (9CI) (CA INDEX NAME)



RN 267891-27-0 CAPLUS
CN Benzamide, N-[2-(4-methoxyphenyl)ethyl]-2-[(4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)



RN 267891-28-1 CAPLUS
CN Benzamide, N-[2-(4-hydroxyphenyl)ethyl]-2-[(4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)



RN 267891-29-2 CAPLUS
CN Benzamide, N-2-pyridinyl-2-[(4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)





RN 267891-30-5 CAPLUS
CN Benzamide, N-(3-pyridinylmethyl)-2-[(4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)



RN 267891-31-6 CAPLUS
CN Benzamide, N-(5-chloro-2-pyridinyl)-2-[(4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)





RN 267891-32-7 CAPLUS
CN Benzamide, N-3-pyridinyl-2-[(4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)





RN 267891-33-8 CAPLUS
CN Benzamide, 2-[(4-pyridinylmethyl)amino]-N-[5-(trifluoromethyl)-1,3,4-thiadiazol-2-yl]- (9CI) (CA INDEX NAME)



RN 267891-34-9 CAPLUS
CN Benzamide, 2-[(4-pyridinylmethyl)amino]-N-[[4-(trifluoromethyl)phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 267891-35-0 CAPLUS
CN Benzamide, N-(5-phenyl-1H-pyrazol-3-yl)-2-[(4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)



RN 267891-36-1 CAPLUS
CN Benzamide, N-(trans-4-phenylcyclohexyl)-2-[(4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 267891-37-2 CAPLUS
CN Benzamide, N-(1-isoquinolinylmethyl)-2-[(4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)



RN 267891-38-3 CAPLUS
CN Benzamide, 2-[(4-pyridinylmethyl)amino]-N-(2-quinolinylmethyl)- (9CI) (CA INDEX NAME)



RN 267891-39-4 CAPLUS
CN Benzamide, 2-[(4-pyridinylmethyl)amino]-N-(1,2,3,4-tetrahydro-7-quinolinyl)- (9CI) (CA INDEX NAME)



RN 267891-40-7 CAPLUS
CN Benzamide, N-(2-phenylcyclohexyl)-2-[(4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)



RN 267891-41-8 CAPLUS
CN Benzamide, N-(2,3-dihydro-1,4-benzodioxin-6-yl)-2-[(4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)



RN 267891-42-9 CAPLUS
CN Benzamide, 2-[(4-pyridinylmethyl)amino]-N-6-quinolinyl- (9CI) (CA INDEX NAME)



RN 267891-43-0 CAPLUS
CN Benzamide, 2-[(4-pyridinylmethyl)amino]-N-2-quinolinyl- (9CI) (CA INDEX NAME)



RN 267891-44-1 CAPLUS
CN Benzamide, N-3-isoquinolinyl-2-[(4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)



RN 267891-45-2 CAPLUS
CN Benzamide, N-1H-indol-5-yl-2-[(4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)



RN 267891-46-3 CAPLUS
CN Benzamide, N-(3-methyl-2-quinolinyl)-2-[(4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)



RN 267891-47-4 CAPLUS
CN Benzamide, N-(6-chloro-3-methyl-2-quinolinyl)-2-[(4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)



RN 267891-48-5 CAPLUS
CN Benzamide, N-(7-chloro-3-methyl-2-quinolinyl)-2-[(4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)



RN 267891-49-6 CAPLUS
CN Benzamide, N-(6-fluoro-3-methyl-2-quinolinyl)-2-[(4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)



RN 267891-50-9 CAPLUS
CN Benzamide, N-(7-fluoro-3-methyl-2-quinolinyl)-2-[(4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)



RN 267891-51-0 CAPLUS
CN Benzamide, N-(6-methoxy-3-methyl-2-quinolinyl)-2-[(4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)



RN 267891-52-1 CAPLUS
CN Benzamide, N-(7-methoxy-3-methyl-2-quinolinyl)-2-[(4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)



RN 267891-53-2 CAPLUS
CN Benzamide, N-(5-chloro-2-quinazolinyl)-2-[(4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)



RN 267891-54-3 CAPLUS
CN Benzamide, 2-chloro-N-[(4-chlorophenyl)methyl]-6-[(4-

pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)



RN 267891-55-4 CAPLUS
CN Benzamide, 2-chloro-6-[(4-pyridinylmethyl)amino]-N-2-quinolinyl- (9CI) (CA INDEX NAME)



RN 267891-56-5 CAPLUS
CN Benzamide, 5-chloro-2-[(4-pyridinylmethyl)amino]-N-2-quinolinyl- (9CI) (CA INDEX NAME)



RN 267891-57-6 CAPLUS
CN Benzamide, 4-fluoro-N-3-isoquinolinyl-2-[(4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)



RN 267891-58-7 CAPLUS
CN Benzamide, 4-chloro-2-[(4-pyridinylmethyl)amino]-N-2-quinolinyl- (9CI) (CA INDEX NAME)



RN 267891-59-8 CAPLUS
CN Benzamide, 4,5-difluoro-N-3-isoquinolinyl-2-[(4-pyridinylmethyl)amino]-
(9CI) (CA INDEX NAME)



RN 267891-61-2 CAPLUS
CN Benzamide, N-[(4-methoxyphenyl)methyl]-2-[[(4-methoxyphenyl)methyl]amino]-
(9CI) (CA INDEX NAME)



RN 267891-63-4 CAPLUS
CN Benzamide, N-[2-(4-chlorophenyl)ethyl]-2-[[(4-hydroxyphenyl)methyl]amino]-
(9CI) (CA INDEX NAME)



RN 267891-64-5 CAPLUS
CN Benzamide, 2-[[(1,6-dihydro-6-oxo-3-pyridinyl)methyl]amino]-N-3-
isoquinolinyl- (9CI) (CA INDEX NAME)



RN 267891-65-6 CAPLUS
CN Benzamide, N-3-isoquinolinyl-2-[(4-pyrimidinylmethyl)amino]- (9CI) (CA INDEX NAME)



RN 267891-66-7 CAPLUS
CN Benzamide, 5-fluoro-N-3-isoquinolinyl-2-[(4-pyrimidinylmethyl)amino]- (9CI) (CA INDEX NAME)



RN 267891-67-8 CAPLUS
CN Benzamide, 4-fluoro-N-1H-indazol-5-yl-2-[(4-pyrimidinylmethyl)amino]- (9CI) (CA INDEX NAME)



RN 267891-68-9 CAPLUS
CN Benzamide, N-1H-indazol-5-yl-2-[(4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)



RN 267891-69-0 CAPLUS
CN Benzamide, N-1H-benzimidazol-2-yl-2-[(4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)



RN 267891-70-3 CAPLUS
CN Benzamide, N-6-benzothiazolyl-5-fluoro-2-[(4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)



RN 267891-72-5 CAPLUS
CN Benzamide, N-(5,6-dimethyl-1H-benzimidazol-2-yl)-2-[(4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)



RN 267891-73-6 CAPLUS
CN Benzamide, N-6-benzothiazolyl-2-[(4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)



RN 267891-74-7 CAPLUS
CN Benzamide, 2-[(4-pyridinylmethyl)amino]-N-[6-(trifluoromethoxy)-2-benzothiazolyl]- (9CI) (CA INDEX NAME)



RN 267891-75-8 CAPLUS
CN Benzamide, N-1H-indazol-6-yl-2-[(4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)



RN 267891-76-9 CAPLUS
CN Benzamide, N-4-pyridinyl-2-[(4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)



RN 267891-77-0 CAPLUS
CN Benzamide, N-(1-methyl-1H-benzimidazol-2-yl)-2-[(4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)



RN 267891-78-1 CAPLUS
CN Benzamide, N-(6-chloro-2-benzothiazolyl)-2-[(4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)



RN 267891-79-2 CAPLUS
CN Benzamide, N-1H-benzimidazol-5-yl-2-[(4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)



RN 267891-80-5 CAPLUS
CN Benzamide, N-(6-fluoro-2-benzothiazolyl)-2-[(4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)



RN 267891-81-6 CAPLUS
CN Benzamide, N-2-benzothiazolyl-5-chloro-2-[(4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)



RN 267891-82-7 CAPLUS
CN Benzamide, 5-fluoro-N-1H-indazol-5-yl-2-[(4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)



RN 267891-83-8 CAPLUS
CN Benzamide, 5-chloro-N-1H-indazol-5-yl-2-[(4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)



RN 267891-84-9 CAPLUS
CN Benzamide, N-2-benzothiazolyl-5-fluoro-2-[(4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)



RN 267891-85-0 CAPLUS
CN Benzamide, N-6-benzothiazolyl-5-chloro-2-[(4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)



IT **267891-92-9 267891-93-0 267891-94-1**
267891-95-2 267891-96-3 267891-97-4
267891-98-5 267891-99-6 267892-01-3
267892-02-4 267892-03-5 267892-04-6
267892-05-7 267892-06-8 267892-07-9
267892-09-1 267892-11-5 267892-14-8
267892-15-9
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(prepn. of anthranilic acid amides as VEGF receptor inhibitors)

RN 267891-92-9 CAPLUS
CN Benzamide, N-(4-pyridinylmethyl)-2-[(4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)



RN 267891-93-0 CAPLUS
CN Benzamide, N-[3-(4-chlorophenyl)propyl]-2-[(4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)



RN 267891-94-1 CAPLUS
CN Benzamide, N-[2-(4-chlorophenyl)propyl]-2-[(4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)



RN 267891-95-2 CAPLUS
CN Benzamide, N-(2-phenylpropyl)-2-[(4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)



RN 267891-96-3 CAPLUS
CN Benzamide, N-(5-chloro-2,3-dihydro-1H-inden-1-yl)-2-[(4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)



RN 267891-97-4 CAPLUS
CN Benzamide, N-[2-(3,4-dimethoxyphenyl)ethyl]-2-[(4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)



RN 267891-98-5 CAPLUS
CN Benzamide, N-2,1,3-benzothiadiazol-5-yl-2-[(4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)



RN 267891-99-6 CAPLUS
CN Benzamide, 2-[(4-pyridinylmethyl)amino]-N-[(1R)-1,2,3,4-tetrahydro-1-naphthalenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 267892-01-3 CAPLUS
CN Benzamide, N-(4-phenylbutyl)-2-[(4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)



RN 267892-02-4 CAPLUS
CN Benzamide, 2-[(4-pyridinylmethyl)amino]-N-[(1S)-1,2,3,4-tetrahydro-1-naphthalenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 267892-03-5 CAPLUS
CN Benzamide, N-(2-phenylethyl)-2-[(4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)



RN 267892-04-6 CAPLUS
CN Benzamide, N-5-isoquinolinyl-2-[(4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)



RN 267892-05-7 CAPLUS
CN Benzamide, N-methyl-N-(2-phenylethyl)-2-[(4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)



RN 267892-06-8 CAPLUS
CN Benzamide, 5-chloro-N-[(4-chlorophenyl)methyl]-2-[(4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)



RN 267892-07-9 CAPLUS
CN Benzamide, 5-chloro-N-(3-phenylpropyl)-2-[(4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)



RN 267892-09-1 CAPLUS
CN Benzamide, 5-fluoro-N-3-isoquinolinyl-2-[(4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)



RN 267892-11-5 CAPLUS
CN Benzamide, 5-chloro-N-3-isoquinolinyl-2-[(4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)



RN 267892-14-8 CAPLUS
CN Benzamide, N-2-benzothiazolyl-4-fluoro-2-[(4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)



RN 267892-15-9 CAPLUS
CN Benzamide, N-(4-chloro-2-benzothiazolyl)-2-[(4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)



IT **267891-90-7**
RL: RCT (Reactant); RACT (Reactant or reagent)
(prepn. of anthranilic acid amides as VEGF receptor inhibitors)
RN 267891-90-7 CAPLUS
CN Benzamide, 2-[[(1,2-dihydro-2-oxo-4-pyridinyl)methyl]amino]-N-3-isoquinolinyl- (9CI) (CA INDEX NAME)



L31 ANSWER 26 OF 55 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2000:643352 CAPLUS

DOCUMENT NUMBER: 133:335148
TITLE: Synthesis of racemic 1,2,3,4-tetrahydroisoquinolines and their resolution
AUTHOR(S): Suna, E.; Trapencieris, P.
CORPORATE SOURCE: Latvian Institute of Organic Synthesis, Riga, LV-1006, Latvia
SOURCE: Chemistry of Heterocyclic Compounds (New York)(Translation of Khimiya Geterotsiklicheskikh Soedinenii) (2000), 36(3), 287-300
CODEN: CHCCAL; ISSN: 0009-3122
PUBLISHER: Consultants Bureau
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 133:335148
ED Entered STN: 14 Sep 2000
AB 1-Aminophenyl-substituted 3,4-dihydroisoquinolines were obtained in various ways using the Bischler-Napieralski reaction. The effect of the protecting group at the aniline N atom on the course of the reaction was studied, and it was found that the N-phthalyl group was stable under the cyclization conditions. The dihydroisoquinolines were reduced to the resp. racemic 1,2,3,4-tetrahydroisoquinolines, which were resolved by crystn. of the diastereomeric tartrates.
IT **304463-96-5P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. and resoln. of tetrahydroisoquinolines)
RN 304463-96-5 CAPLUS
CN Benzamide, 2-[methyl(phenylmethyl)amino]-N-(2-phenylethyl)- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 23 THERE ARE 23 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L31 ANSWER 27 OF 55 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1999:691067 CAPLUS
DOCUMENT NUMBER: 131:310451
TITLE: Preparation of anthranilamides as of cGMP-phosphodiesterase inhibitors
INVENTOR(S): Oku, Teruo; Sawada, Kozo; Kuroda, Akio; Inoue, Takayuki; Kayakiri, Natsuko; Sawada, Yuki; Mizutani, Tsuyoshi
PATENT ASSIGNEE(S): Fujisawa Pharmaceutical Co., Ltd., Japan
SOURCE: PCT Int. Appl., 192 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9954284	A1	19991028	WO 1999-JP2028	19990415

W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ,

DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS,
JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN,
MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM,
TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD,
RU, TJ, TM
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK,
ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG,
CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

CA 2328413	AA	19991028	CA 1999-2328413	19990415
AU 9931708	A1	19991108	AU 1999-31708	19990415
AU 758298	B2	20030320		
BR 9909781	A	20001219	BR 1999-9781	19990415
EP 1080069	A1	20010307	EP 1999-913686	19990415
EP 1080069	B1	20030319		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI				
JP 2001508811	T2	20010703	JP 1999-552766	19990415
AT 234810	E	20030415	AT 1999-913686	19990415
ZA 2000005243	A	20020114	ZA 2000-5243	20000928
US 6384080	B1	20020507	US 2001-509541	20010423
US 2002193614	A1	20021219	US 2002-50789	20020118

PRIORITY APPLN. INFO.:

AU 1998-3085	A	19980420
AU 1998-5851	A	19980911
AU 1998-7781	A	19981218
WO 1999-JP2028	W	19990415
US 2001-509541	A1	20010423

OTHER SOURCE(S): MARPAT 131:310451
ED Entered STN: 29 Oct 1999
GI



II

AB R4NHZ1CONHZR3 [I; R3 = H, OH, alkoxy, aryl, etc.; R4 = alkoxy, heterocyclyl, (alkyl)amino, etc.; Z = alkylene; Z1 = e-withdrawing group-substituted (halo)-1,2-phenylene] were prepd. Thus, 2-fluoro-5-nitrobenzoic acid was amidated by 1,3-benzodioxole-5-methylamine and the product aminated by 4-aminocyclohexanol to give, after oxidn., title compd. II. Data for biol. activity of I were given.

IT **247569-27-3P 247570-30-5P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of anthranilamides as of cGMP-phosphodiesterase inhibitors)

RN 247569-27-3 CAPLUS

CN Benzamide, 5-cyano-N-[(3,4-dimethoxyphenyl)methyl]-2-[[(1S)-2-(1H-imidazol-1-yl)-1-methylethyl]amino]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 247570-30-5 CAPLUS
CN Benzamide, 5-cyano-N-[(3,4-dimethoxyphenyl)methyl]-2-[[(1S)-1-methyl-2-(2-methyl-1H-imidazol-1-yl)ethyl]amino]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L31 ANSWER 28 OF 55 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1999:421679 CAPLUS
DOCUMENT NUMBER: 131:87925
TITLE: Preparation of heteroarylcarbonylaminobenzamides and related compounds as anticoagulants.
INVENTOR(S): Arnaiz, Damian O.; Chou, Yuo-Ling; Karanjawala, Rushad E.; Kochanny, Monica J.; Lee, Wheeseong; Liang, Amy Mei; Morrissey, Michael M.; Phillips, Gary B.; Sacchi, Karna Lyn; Sakata, Stephen T.; Shaw, Kenneth J.; Snider, R. Michael; Wu, Shung C.; Ye, Bin; Zhao, Zuchun; Griedel, Brian D.

PATENT ASSIGNEE(S): Schering Aktiengesellschaft, Germany
SOURCE: PCT Int. Appl., 326 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9932477	A1	19990701	WO 1998-EP7650	19981127
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 6140351	A	20001031	US 1998-187459	19981105
CA 2315070	AA	19990701	CA 1998-2315070	19981127
AU 9918759	A1	19990712	AU 1999-18759	19981127
AU 751856	B2	20020829		
EP 1040108	A1	20001004	EP 1998-963519	19981127
EP 1040108	B1	20040225		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
JP 2001526283	T2	20011218	JP 2000-525414	19981127
NZ 503809	A	20020426	NZ 1998-503809	19981127
NO 2000003111	A	20000818	NO 2000-3111	20000616

PRIORITY APPLN. INFO.: US 1997-994284 A 19971219
US 1998-187459 A 19981105
WO 1998-EP7650 W 19981127

OTHER SOURCE(S): MARPAT 131:87925
ED Entered STN: 08 Jul 1999
GI



I

AB Title compds. [I; m = 1-3; n = 1-5; B, Q = atoms to form aryl, heterocyclyl rings; D, E = NR5CX; R8NR5CX, NR5SOp, etc.; p = 0-2; X = O, S, H2; R1 = H, alkyl, aryl, aralkyl, halo, haloalkyl, cyano, OR5, CO2R5, NR5R6, CONR5R6 (substituted) heterocyclyl, etc.; R2 = H, alkyl, aryl, aralkyl, halo, haloalkyl, cyano, OR5, CO2R5, CONR5R6, etc.; R3 = (substituted) heterocyclyl, aryl; R4 = H, alkyl, halo, haloalkyl, cyano, NO2, OR5, CO2R5, NR5R6, etc.; R5, R6 = H, alkyl, aryl, aralkyl; R8 = alkylene, alkenylene, alkynylene], were prepd. Thus, N-(4-chlorophenyl)-2-[[(4-chloromethyl)-3-chlorothiophen-2-ylcarbonyl]amino]-3-methoxy-5-chlorobenzamide in DMF at 0.degree. was treated with N-methylpiperazine followed by stirring to room temp. to give N-(4-chlorophenyl)-2-[[[4-[(4-methylpiperazin-1-yl)methyl]-3-chlorothiophen-2-yl]carbonyl]amino]-3-methoxy-5-chlorobenzamide. Title compds. routinely inhibited Factor Xa with Ki<3 nM. An aerosol formulation is given.

IT **229339-81-5P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological

study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of heteroarylcarbonylaminobenzamides and related compds. as anticoagulants)

RN 229339-81-5 CAPLUS

CN Benzamide, N-(4-chlorophenyl)-2-[[(3-methylbenzo[b]thien-2-yl)methyl]amino]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L31 ANSWER 29 OF 55 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1999:409260 CAPLUS
DOCUMENT NUMBER: 131:73440
TITLE: Preparation of aromatic amide derivatives as ACC inhibitor
INVENTOR(S): Igawa, Hiroshi; Nishimura, Masato; Okada, Keiji; Nakamura, Takashi
PATENT ASSIGNEE(S): Fujirebio, Inc., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 72 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 11171848	A2	19990629	JP 1998-270721	19980925

PRIORITY APPLN. INFO.: JP 1997-277942 19970926
OTHER SOURCE(S): MARPAT 131:73440
ED Entered STN: 02 Jul 1999
GI



I

AB Title compds. [I; R = 3-CF3C6H4, C6H5(CH2)2, C6H5, CH3(CH2)5, CH3(CH2)3, CH3(CH2)2, CH3CH2, CH3, C6H5(CH2)3, etc.; R1 = H, CH3(CH2)4, 5-CH3(CH2)5CC, 5-CH3CH2CC, 5-(CH3)3CCC, 4-C6H5CH2O, 4-C6H5CC, 3-C6H5CC, 3-C6H5CC, 3-(4-NO2C6H4)CC, 3-(4-NCC6H4)CC, 3-(4-HOC6H4)CC, etc.; R2 =

5-OH, 5-Cl, 5-OMe, 5-Me, 5-Br, etc.; R3 = H, CH3, etc.; R4 = CO2H, AcNHSO2, CH3(CH2)4CONHSO2, 4-CF3C6H4CONHSO2, PHCONHSO2, (CH3)3CONHSO2, CH3(CH2)2NHCONHSO2, etc.; X = CH, N; dotted bond = single, double] are prepd. and tested as ACC (acetyl-CoA carboxylase) inhibitors in treatment of lipids oxidn. related diseases, such as myocardial infarction, cerebral infarction, and diabetes. The title compd. I (R = 3-CF3C6H4; R1 = H; R2 = H; R3 = H; X = CH; dotted bonds were double bonds) was prepd. with 72% yield from 3-EtO2CC6H4NH2 and 3-(2-HO2CC6H4NH)C6H4CF3.

IT **228580-72-1P 228580-91-4P 228580-97-0P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(prepn. of arom. amide derivs. as ACC inhibitor)

RN 228580-72-1 CAPLUS
CN Benzoic acid, 2-[[4-(phenylethynyl)-2-[(phenylmethyl)amino]benzoyl]amino]- (9CI) (CA INDEX NAME)



RN 228580-91-4 CAPLUS
CN Benzoic acid, 2-[[4-(phenylethynyl)-2-[(3-phenylpropyl)amino]benzoyl]amino]- (9CI) (CA INDEX NAME)



RN 228580-97-0 CAPLUS
CN Benzoic acid, 2-[[2-[(2-phenylethyl)amino]-5-(phenylethynyl)benzoyl]amino]- (9CI) (CA INDEX NAME)



IT **228580-60-7P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. of arom. amide derivs. as ACC inhibitor)

RN 228580-60-7 CAPLUS
CN Benzoic acid, 2-[[2-[(phenylmethyl)amino]benzoyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)



IT **228580-61-8P 228580-84-5P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of arom. amide derivs. as ACC inhibitor)
RN 228580-61-8 CAPLUS
CN Benzoic acid, 2-[[2-[(phenylmethyl)amino]benzoyl]amino]- (9CI) (CA INDEX NAME)



RN 228580-84-5 CAPLUS
CN Benzoic acid, 2-[[2-[(3-phenylpropyl)amino]benzoyl]amino]- (9CI) (CA INDEX NAME)



L31 ANSWER 30 OF 55 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1997:265454 CAPLUS
DOCUMENT NUMBER: 126:277494
TITLE: Preparation of piperazinylbenzamides, piperidylbenzamides, and analogs thereof as inflammation and allergy inhibitors
INVENTOR(S): Kawagoe, Keiichi; Shidonii, Kurifuoodo Baafuoodo; Yokohama, Shuichi; Miwa, Tamotsu; Nakajima, Hiroto; Tsukada, Wataru
PATENT ASSIGNEE(S): Daiichi Seiyaku Co, Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 67 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

JP 09059236 A2 19970304 JP 1995-214431 19950823
PRIORITY APPLN. INFO.: JP 1995-214431 19950823
OTHER SOURCE(S): MARPAT 126:277494
ED Entered STN: 25 Apr 1997
GI



I

AB The title compds. I [R1 = halo, etc.; R2 = halo, nitro, etc.; A = C(:Z)NR3R4, etc.; Z = O, etc.; R3 = (un)substituted arom. hydrocarbon, etc.; R4 = H, etc.] are prepd. N-(4-Chlorophenyl)-3-(4-methyl-1-piperazinyl)-2-nitrobenzamide at 50 mg/kg orally gave 79% inhibition of adjuvant arthritis in rats.

IT **188602-70-2P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of piperazinylbenzamides, piperidylbenzamides, and analogs thereof as inflammation and allergy inhibitors)

RN 188602-70-2 CAPLUS
CN Benzamide, 3-chloro-N-(4-chlorophenyl)-2-[(2-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)



L31 ANSWER 31 OF 55 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1995:858623 CAPLUS
DOCUMENT NUMBER: 123:256357
TITLE: Preparation of anthranilic acid amide derivative as cyclic guanosine monophosphate-phosphodiesterase inhibitors
INVENTOR(S): Ozaki, Fumihiro; Ishibashi, Keiji; Ikuta, Hironori; Ishihara, Hiroki; Souda, Shigeru
PATENT ASSIGNEE(S): Japan
SOURCE: PCT Int. Appl., 204 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9518097	A1	19950706	WO 1994-JP2262	19941227

W: AU, CA, CN, FI, HU, KR, NO, NZ, RU, US
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE

CA 2155662	AA	19950706	CA 1994-2155662	19941227
AU 9512824	A1	19950717	AU 1995-12824	19941227
AU 694465	B2	19980723		
EP 686625	A1	19951213	EP 1995-903999	19941227
EP 686625	B1	19990526		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
CN 1118595	A	19960313	CN 1994-191311	19941227
JP 08188563	A2	19960723	JP 1994-336920	19941227
HU 74450	A2	19961230	HU 1995-2512	19941227
RU 2128644	C1	19990410	RU 1995-120194	19941227
AT 180468	E	19990615	AT 1995-903999	19941227
FI 9503968	A	19951019	FI 1995-3968	19950823
NO 9503305	A	19951025	NO 1995-3305	19950823
US 5716993	A	19980210	US 1995-507476	19950914

PRIORITY APPLN. INFO.: JP 1993-347092 A 19931227
JP 1994-299110 A 19941109
WO 1994-JP2262 W 19941227

OTHER SOURCE(S): MARPAT 123:256357
ED Entered STN: 17 Oct 1995
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Anthranilamide derivs. [I; R1, R2, R3, R4 = H, halo, OH, (halo)alkyl, (halo)alkoxy, nitro, hydroxyalkyl, cyano, (CH2)pNR9R10, S(O)qR13, (un)protected CO2H, (un)substituted tetrazolyl, CONH2, pyrazolyl, or imidazolyl; or adjacent two substituents selected from R1 - R4 together with the C atoms bonded to them forms a ring; wherein R9, R10 = H, (halo)alkyl, arylalkyl, heteroarylalkyl, acyl, (un)protected CO2H; or NR9R10 forms a ring; p = 0, 1-6; R13 = H, (halo)alkyl; q = 0, 1-2; R5, R6 = H, halo, OH, cyano, (halo)alkyl, (halo)alkoxy; or R5 and R6 together with the C atoms bonded to them form cycloalkane, oxolane, 1,3-dioxolane, or 1,4-dioxane ring; W = N, CH; R7, R8 = H, (halo)alkyl; or R1 and R7 together with the C atoms bonded to them form a ring optionally contg. other N, O, or S atom; A = H, (halo)alkyl, X(CH2)mZ; wherein X = CO, CS, CH2, SO2; Z = OH, (halo)alkoxy, cyano, halo, etc.; Y = O, S; n = 0, 1-6] or pharmacol. acceptable salts thereof are prepd. These compds. are useful for the treatment of ischemic heart disease, angina pectoris, hypertension, pulmonary hypertension, heart failure, and asthma. Thus, 2-nitro-5-chlorobenzoic acid was refluxed with SOCl2 in benzene for 4 h and concd. to give 2-nitro-5-chlorobenzoyl chloride which was amidated with piperonylamine in the presence of Et3N in THF to give a benzamide (II; R = NO2). This compd. was reduced by Fe powder in a mixt. of AcOH, H2O, and MeOH under gentle refluxing to give, after concn. and treatment with concd. HCl in EtOH, N-piperonylanthranilamide deriv. II. HCl (R = NH2). An anthranilamide deriv. (III) showed IC50 of 0.4 nM against cyclic guanosine monophosphate-phosphodiesterase prepn. from pig aorta.

IT **169043-60-1P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of anthranilamide derivs. as cyclic guanosine monophosphate-phosphodiesterase inhibitors)

RN 169043-60-1 CAPLUS

CN Benzamide, N-(1,3-benzodioxol-5-ylmethyl)-5-chloro-2-[(4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)



RN 139602-66-7 CAPLUS
CN Benzamide, 2-[[(2,4-dimethoxyphenyl)methyl]amino]-N-(3-methylphenyl)-
(9CI) (CA INDEX NAME)





RN 139602-67-8 CAPLUS
CN Benzamide, 2-[[(2,4-dimethoxyphenyl)methyl]amino]-N-(4-methylphenyl)-
(9CI) (CA INDEX NAME)



RN 139602-68-9 CAPLUS
CN Benzamide, N-(4-chlorophenyl)-2-[[(2,4-dimethoxyphenyl)methyl]amino]-
(9CI) (CA INDEX NAME)



L31 ANSWER 32 OF 55 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1992:571361 CAPLUS
DOCUMENT NUMBER: 117:171361
TITLE: Synthesis of biologically active 4(3H)-quinazolinonium perchlorates
AUTHOR(S): Chernobrovin, N. I.; Kozhevnikov, Yu. V.; Morozova, G. E.; Chernobrovina, T. A.
CORPORATE SOURCE: Perm. Farm. Inst., Perm, Russia
SOURCE: Khimiko-Farmatsevticheskii Zhurnal (1992), 26(3), 48-51
CODEN: KHFZAN; ISSN: 0023-1134
DOCUMENT TYPE: Journal
LANGUAGE: Russian
ED Entered STN: 01 Nov 1992
GI



I

AB Title salts I (R = H, 3-Me, 4-Me, 4-MeO, 4-Cl; R1 = OMe, R2 = H; R1 = H, R2 = OMe) were prepd. by condensation of anthranilanilides with dimethoxybenzaldehydes, followed by borohydride redn. of the imine group, N-acetylation, and acid cyclization. The acute toxicity and anticonvulsant, analgesic, and antimicrobial activities of some I were tested.

IT **139602-64-5P 139602-66-7P 139602-67-8P**
139602-68-9P 139602-69-0P 139602-71-4P
139602-72-5P 139602-73-6P 143424-22-0P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. and acetylation of)

RN 139602-64-5 CAPLUS
CN Benzamide, 2-[[(2,4-dimethoxyphenyl)methyl]amino]-N-phenyl- (9CI) (CA INDEX NAME)



RN 139602-69-0 CAPLUS
CN Benzamide, 2-[[(3,4-dimethoxyphenyl)methyl]amino]-N-phenyl- (9CI) (CA INDEX NAME)



RN 139602-71-4 CAPLUS
CN Benzamide, 2-[[(3,4-dimethoxyphenyl)methyl]amino]-N-(3-methylphenyl)- (9CI) (CA INDEX NAME)



RN 139602-72-5 CAPLUS
CN Benzamide, 2-[[(3,4-dimethoxyphenyl)methyl]amino]-N-(4-methylphenyl)- (9CI) (CA INDEX NAME)



RN 139602-73-6 CAPLUS
CN Benzamide, N-(4-chlorophenyl)-2-[[(3,4-dimethoxyphenyl)methyl]amino]- (9CI) (CA INDEX NAME)



RN 143424-22-0 CAPLUS
CN Benzamide, 2-[[(2,4-dimethoxyphenyl)methyl]amino]-N-(4-methoxyphenyl)-
(9CI) (CA INDEX NAME)



L31 ANSWER 33 OF 55 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1992:128388 CAPLUS
DOCUMENT NUMBER: 116:128388
TITLE: Arylamides of N-(p-2',4'- or -3',4'-dimethoxybenzyl)anthranilic acid
INVENTOR(S): Chernobrovin, N. I.; Kozhevnikov, Yu. V.; Zalesov, V. S.; Semenova, Z. N.
PATENT ASSIGNEE(S): Perm Pharmaceutical Institute, USSR
SOURCE: U.S.S.R. From: Otkrytiya, Izobret. 1991, (28), 258.
CODEN: URXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Russian
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
SU 1156362	A1	19910730	SU 1983-3573020	19830217

PRIORITY APPLN. INFO.: SU 1983-3573020 19830217
ED Entered STN: 03 Apr 1992
GI



I

AB The title compds. (I; R = H, Me, p-Cl; R1 o-OMe, m-OMe) are intermediates for biol. active 1-(2',4'- or -3',4'-dimethoxybenzyl)-2-methyl-3-aryl-4-(3H)-quinazolinonium perchlorates.

IT **139602-64-5 139602-65-6 139602-66-7**
139602-67-8 139602-68-9 139602-69-0
139602-70-3 139602-71-4 139602-72-5
139602-73-6
RL: RCT (Reactant); RACT (Reactant or reagent)
(intermediate for quinazolinonium perchlorate derivs.)

RN 139602-64-5 CAPLUS

CN Benzamide, 2-[[(2,4-dimethoxyphenyl)methyl]amino]-N-phenyl- (9CI) (CA INDEX NAME)



RN 139602-65-6 CAPLUS

CN Benzamide, 2-[[(2,4-dimethoxyphenyl)methyl]amino]-N-(2-methylphenyl)-(9CI) (CA INDEX NAME)



RN 139602-66-7 CAPLUS

CN Benzamide, 2-[[(2,4-dimethoxyphenyl)methyl]amino]-N-(3-methylphenyl)-(9CI) (CA INDEX NAME)





RN 139602-67-8 CAPLUS

CN Benzamide, 2-[[(2,4-dimethoxyphenyl)methyl]amino]-N-(4-methylphenyl)-(9CI) (CA INDEX NAME)



RN 139602-68-9 CAPLUS
CN Benzamide, N-(4-chlorophenyl)-2-[[(2,4-dimethoxyphenyl)methyl]amino]- (9CI) (CA INDEX NAME)



RN 139602-69-0 CAPLUS
CN Benzamide, 2-[[(3,4-dimethoxyphenyl)methyl]amino]-N-phenyl- (9CI) (CA INDEX NAME)



RN 139602-70-3 CAPLUS
CN Benzamide, 2-[[(3,4-dimethoxyphenyl)methyl]amino]-N-(2-methylphenyl)- (9CI) (CA INDEX NAME)





RN 139602-71-4 CAPLUS
CN Benzamide, 2-[[(3,4-dimethoxyphenyl)methyl]amino]-N-(3-methylphenyl)-(9CI) (CA INDEX NAME)



RN 139602-72-5 CAPLUS
CN Benzamide, 2-[[(3,4-dimethoxyphenyl)methyl]amino]-N-(4-methylphenyl)-(9CI) (CA INDEX NAME)



RN 139602-73-6 CAPLUS
CN Benzamide, N-(4-chlorophenyl)-2-[[(3,4-dimethoxyphenyl)methyl]amino]-(9CI) (CA INDEX NAME)



L31 ANSWER 34 OF 55 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1989:457672 CAPLUS
DOCUMENT NUMBER: 111:57672
TITLE: Syntheses of heterocycles with 5-phenylisoxazolium salts. III. Synthesis of pyrrolo[1,2-a]quinazolin-5-ones
AUTHOR(S): Henning, Hans Georg; Haber, Hanka
CORPORATE SOURCE: Sekt. Chem., Humboldt-Univ., Berlin, DDR-1040, Ger. Dem. Rep.
SOURCE: Monatshefte fuer Chemie (1988), 119(12), 1405-14
CODEN: MOCMB7; ISSN: 0026-9247
DOCUMENT TYPE: Journal
LANGUAGE: German
OTHER SOURCE(S): CASREACT 111:57672
ED Entered STN: 20 Aug 1989

GI



AB Refluxing EtOH-AcOH solns. of N-aroyl-N-methylbenzoylacetamides, 2-PhCOCH2CONMeCOC6H4NHCHRCOR1 (I; R = H, R1 = OMe, Ph, 4-FC6H4; R = R1 = Ph), causes elimination of acetophenone and generation of N(1)-substituted N(3)-methyl-1H,3H-quinazoline-2,4-diones II. In contrast, at room temp. in Ac2O I eliminate water yielding 2-benzoylmethylenequinazolinones, which at 60 .degree.C cyclize to pyrrolo[1,2-a]quinazolin-5-ones III. This transformation may be explained in terms of a normal Knorr reaction. A anomalous Knorr reaction was obsd. in the case of the more rigid 2-phenacylidenequinazolinone leading to a diasteromeric mixt. of pyrroloquinazolinone IV in kinetically controlled reaction. Favored by intramol. hydrogen bonding cis IV converts to the thermodynamically more stable III by warming the ethanolic soln. for 3 h.

IT **114515-04-7P 114515-05-8P 114515-06-9P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. and cyclization of)

RN 114515-04-7 CAPLUS

CN Benzenepropanamide, N-methyl-.beta.-oxo-N-[2-[(2-oxo-2-phenylethyl)amino]benzoyl]- (9CI) (CA INDEX NAME)



RN 114515-05-8 CAPLUS

CN Benzenepropanamide, N-[2-[[2-(4-fluorophenyl)-2-oxoethyl]amino]benzoyl]-N-methyl-.beta.-oxo- (9CI) (CA INDEX NAME)



RN 114515-06-9 CAPLUS
CN Benzenepropanamide, N-methyl-.beta.-oxo-N-[2-[(2-oxo-1,2-diphenylethyl)amino]benzoyl]- (9CI) (CA INDEX NAME)



L31 ANSWER 35 OF 55 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1988:221379 CAPLUS
DOCUMENT NUMBER: 108:221379
TITLE: Syntheses of heterocycles from 5-phenylisoxazolium salts. 1. Synthesis and thermal behavior of .beta.-keto imides
AUTHOR(S): Henning, Hans Georg; Haber, Hanka
CORPORATE SOURCE: Sekt. Chem., Humboldt-Univ. Berlin, Berlin, DDR-1040, Ger. Dem. Rep.
SOURCE: Zeitschrift fuer Chemie (1987), 27(8), 290-2
CODEN: ZECEAL; ISSN: 0044-2402
DOCUMENT TYPE: Journal
LANGUAGE: German
OTHER SOURCE(S): CASREACT 108:221379
ED Entered STN: 24 Jun 1988
AB Ring cleavage reaction of 5-phenylisoxazolium salt with RCO2H (R = Me, CH2CH2NH2, CH2CH2NHCH2Ph, Ph, 2-C6H4NHR1; R1 = H, Me, Ph, CH2CO2Me, CH2COPh, CH2COC6H4F-4, CHPhCOPh) gave 48-92% PhCOCH2CONMeCOR (I), intermediate for the synthesis of heterocycles. I (R = Me, Ph) were O-acylated with sodium acetate and benzoate. O-Acylated products rearranged to N-acylated product in alc. at 30-40.degree..
IT **114515-04-7P 114515-05-8P 114515-06-9P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)
RN 114515-04-7 CAPLUS
CN Benzenepropanamide, N-methyl-.beta.-oxo-N-[2-[(2-oxo-2-phenylethyl)amino]benzoyl]- (9CI) (CA INDEX NAME)



RN 114515-05-8 CAPLUS
CN Benzenepropanamide, N-[2-[[2-(4-fluorophenyl)-2-oxoethyl]amino]benzoyl]-N-methyl-.beta.-oxo- (9CI) (CA INDEX NAME)



RN 114515-06-9 CAPLUS
CN Benzenepropanamide, N-methyl-.beta.-oxo-N-[2-[(2-oxo-1,2-diphenylethyl)amino]benzoyl]- (9CI) (CA INDEX NAME)



L31 ANSWER 36 OF 55 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1985:78876 CAPLUS
DOCUMENT NUMBER: 102:78876
TITLE: N-(.omega.-[1H-Imidazol-1-yl]alkyl)arylamides
INVENTOR(S): Wright, William Blythe, Jr.; Press, Jeffery Bruce
PATENT ASSIGNEE(S): American Cyanamid Co. , USA
SOURCE: Ger. Offen., 58 pp.
CODEN: GWXXBX
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 3406416	A1	19840830	DE 1984-3406416	19840222
US 4568687	A	19860204	US 1984-570160	19840113
EP 117462	A2	19840905	EP 1984-101226	19840207
EP 117462	A3	19860820		
R: AT, BE, CH, FR, GB, IT, LI, NL, SE				
DK 8400778	A	19840829	DK 1984-778	19840220

AU 8425072	A1	19840906	AU 1984-25072	19840227
JP 59164779	A2	19840917	JP 1984-34474	19840227
ZA 8401447	A	19841031	ZA 1984-1447	19840227
HU 33785	O	19841228	HU 1984-776	19840227
DD 218890	A5	19850220	DD 1984-260356	19840227

PRIORITY APPLN. INFO.: US 1983-470112 19830228
OTHER SOURCE(S): CASREACT 102:78876
ED Entered STN: 09 Mar 1985
GI



AB The title compds. [I; R = 1-naphthyl, 2-naphthyl, Ph2CH, 9-fluorenyl, (un)substituted Ph; R1 = H, alkyl, PhCH2; R2, R3 = H, alkyl, Ph; Z = CH:CH, OCH2, CO, CnH2n, cyclopropylidene, 1,2-cyclopropanediyl, cyclopentylmethylene; Z1 = CmH2m, CH2CH:CHCH2, CH2C.tplbond.CCH2, CHPhCH2CH2; n = 0-3; m = 2-8] were prepd. Thus, 1H-imidazole-1-propanamine-2HCl was stirred at room temp. in CH2Cl2 with aq. NaOH and 3-ClC6H4COCl to give II. I are effective in vitro inhibitors of thromboxane synthetase at a concn. of 10-4 (units not given) and antihypertensives in rats at 100 mg/kg orally.

IT **93668-03-2P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn., antihypertensive, and platelet aggregation inhibiting activity of)

RN 93668-03-2 CAPLUS
CN Benzamide, N-[3-(1H-imidazol-1-yl)propyl]-2-[(phenylmethyl)amino]- (9CI) (CA INDEX NAME)



L31 ANSWER 37 OF 55 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1984:611088 CAPLUS
DOCUMENT NUMBER: 101:211088
TITLE: Studies of 4[3H]-quinazolone. XII. Synthesis and biological activity of 1-benzyl(4'-nitrobenzyl)-2-methyl-3-alkyl(aryl)-4(3H)-quinazolinone perchlorates
AUTHOR(S): Chernobrovin, N. I.; Kozhevnikov, Yu. V.; Zalesov, V. S.; Gradel, I. I.

CORPORATE SOURCE: Perm. Farm. Inst., Perm, USSR
SOURCE: Khimiko-Farmatsevticheskii Zhurnal (1984), 18(7), 830-3
CODEN: KHFZAN; ISSN: 0023-1134
DOCUMENT TYPE: Journal
LANGUAGE: Russian
GI



I

AB The title compds. I (R = 2,4-xylyl, 4-MeOC6H4, Bu, hexyl, R1 = H; R = 4-MeOC6H4, 4-EtOC6H4, R1 = NO2) were prepd. in 58.6-83.4% yields by acetylation of o-RNHCOC6H4NR2CH2C6H4R1-p (II, R2 = H) to give 61.3-98.1% II (R2 = Ac) which were cyclized by refluxing in MeOH contg. 57% HClO4. I (R = 4-MeOC6H4, R1 = NO2) was an effective antispasmodic for white mice at 150 mg/kg dosage.

IT **92944-76-8P 92944-77-9P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. and acetylation of)

RN 92944-76-8 CAPLUS
CN Benzamide, N-(2,4-dimethylphenyl)-2-[(phenylmethyl)amino]- (9CI) (CA INDEX NAME)



RN 92944-77-9 CAPLUS
CN Benzamide, N-(4-methoxyphenyl)-2-[(phenylmethyl)amino]- (9CI) (CA INDEX NAME)



L31 ANSWER 38 OF 55 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1984:34516 CAPLUS
DOCUMENT NUMBER: 100:34516
TITLE: New synthesis of 11-acyl-5,11-dihydro-6H-pyrido[2,3-b][1,4]benzodiazepin-6-ones and related studies
AUTHOR(S): Kovac, T.; Oklobdzija, M.; Comisso, G.; Decorte, E.;

Fajdiga, T.; Moimas, F.; Angeli, C.; Zonno, F.; Toso, R.; Sunjic, V.
CORPORATE SOURCE: Chem. Res. Co., San Giovanni, Italy
SOURCE: Journal of Heterocyclic Chemistry (1983), 20(5), 1339-49
CODEN: JHTCAD; ISSN: 0022-152X
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 100:34516
ED Entered STN: 12 May 1984
GI



I

AB 11-Acyl-5,11-dihydro-6H-pyrido[2,3-b][1,4]benzodiazepin-6-ones I (R = 4-methylpiperazino, imidazolo, 2-methylimidazolo) were prepd. via N-.alpha.-chloroacetylation and aminolysis. Other attempts at cyclization to form I are also reported.
IT **88369-73-7P 88369-74-8P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)
RN 88369-73-7 CAPLUS
CN Benzamide, N-(2-chloro-3-pyridinyl)-2-[(phenylmethyl)amino]- (9CI) (CA INDEX NAME)



RN 88369-74-8 CAPLUS
CN Benzamide, N-(2-chloro-1-oxido-3-pyridinyl)-2-[(phenylmethyl)amino]- (9CI) (CA INDEX NAME)



L31 ANSWER 39 OF 55 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1983:126006 CAPLUS
DOCUMENT NUMBER: 98:126006

TITLE: Synthesis of 4(3H)-quinazolinones from derivatives of methyl 2-isothiocyanatobenzoate
AUTHOR(S): Dean, William D.; Papadopoulos, Eleftherios P.
CORPORATE SOURCE: Dep. Chem., Univ. New Mexico, Albuquerque, NM, 87131, USA
SOURCE: Journal of Heterocyclic Chemistry (1982), 19(5), 1117-24
CODEN: JHTCAD; ISSN: 0022-152X
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 98:126006
ED Entered STN: 12 May 1984
GI



I



II



III



IV



V

AB 2-MeO2CC6H4NHC(S)OEt, 2-EtO2CC6H4NHC(S)C6H4OMe-4, and I cyclocondensed with nucleophilic amines RNH2 [R = H, OH, NH2, NHMe, NHPh, Bu, Ph, PhCH2, (CH2)nR1; R1 = OH, SH, NH2, NHAc, NHCONHPh; n = 2,3] to give quinazolinones II (R2 = OEt, C6H4OMe-4). Condensed quinazolines III, IV (n = 2,3), and V were similarly prepd.

IT **85094-67-3P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. and cyclocondensation with benzylamine)

RN 85094-67-3 CAPLUS

CN Benzamide, 2-[[(4-methoxyphenyl)thioxomethyl]amino]-N-(phenylmethyl)-(9CI) (CA INDEX NAME)



L31 ANSWER 40 OF 55 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1981:515322 CAPLUS
DOCUMENT NUMBER: 95:115322
TITLE: Carboxylic acid derivatives and medicaments containing them
INVENTOR(S): Griss, Gerhart; Sauter, Robert; Grell, Wolfgang; Hurnaus, Rudolf; Rupprecht, Eckhard; Kaubisch, Nikolaus; Kaehling, Joachim; Eisele, Bernhard; Piper, Helmut; Noll, Klaus
PATENT ASSIGNEE(S): Thomae, Dr. Karl, G.m.b.H., Fed. Rep. Ger.
SOURCE: Eur. Pat. Appl., 271 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 23569	A1	19810211	EP 1980-103670	19800628
EP 23569	B1	19830622		
R: AT, BE, CH, DE, FR, GB, IT, LU, NL, SE				
DE 2928352	A1	19810115	DE 1979-2928352	19790713
DE 2949259	A1	19810611	DE 1979-2949259	19791207
DE 3016650	A1	19811105	DE 1980-3016650	19800430
DE 3016651	A1	19811105	DE 1980-3016651	19800430
EP 63826	A2	19821103	EP 1982-104991	19800628
EP 63826	A3	19821229		
EP 63826	B1	19841205		
R: AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE				
AT 3862	E	19830715	AT 1980-103670	19800628
AT 10632	E	19841215	AT 1982-104991	19800628
AU 8060362	A1	19810115	AU 1980-60362	19800711
AU 535924	B2	19840412		
HU 27876	O	19831128	HU 1983-1085	19800711
HU 186675	B	19850930	HU 1980-1085	19800711
ES 501882	A1	19820301	ES 1981-501882	19810505
ES 501883	A1	19820301	ES 1981-501883	19810505
ES 501884	A1	19820301	ES 1981-501884	19810505
NO 8403735	A	19810114	NO 1984-3735	19840919

PRIORITY APPLN. INFO.:
DE 1979-2928352 A 19790713
DE 1979-2949259 A 19791207
DE 1980-3016650 A 19800430
DE 1980-3016651 A 19800430
EP 1980-103670 A 19800628
EP 1982-104991 19800628

OTHER SOURCE(S): CASREACT 95:115322
ED Entered STN: 12 May 1984
GI



I



III

AB Carboxamides I [R = H, Cl, Br, C4-7 cyclic alkylenimins; R1 = H, F, Cl, Br, C1-6 alkyl or alkoxy, Ph-substituted C1-3 alkoxy, OH, NO2, NH2, cyano, CO2H, alkanoylamine, alkoxycarbonyl, di-C1-3-alkylamidosulfonyl; R2, R3 independently = C1-7 alkyl C3-7 alkenyl or cycloalkyl, Ph-substituted C1-3 alkyl, Ph, adamantyl; NR2R3 = C4-6 cyclic (un)substituted alkylenimins optionally with CH2 replaced by O, S, CO, S(O), S(O2), C7-10 azabicycloalkyl, alkyl-substituted piperidino, C6-9 1,4-dioxa-8-azaspiroalkyl, (CH2)nN (n = 3-5, 7-12); R4 = H, C1-3 alkyl; R5 = H, halo, NO2, NH2, cyano, CHO, CH2OH, CH2CH2CO2H, (esterified) CO2H, substituted Me, Ac, Et, H2NCO, piperidino-, morpholino-, thiomorpholino-, or N-alkylpiperazinocarbonyl; X = N or CH; Z = O, an imino group, or a methylene group optionally subst. with 1 or 2 C1-C3 alkyl groups] and their physiol. tolerable salts, useful as hypoglycemics, anticholesteremics, and hypolipemics (data tabulated), were prepd. by numerous methods. Refluxing 2,5-Cl(O2N)C6H3CO2H and 2-methylpiperdine in EtOH gave 85% 2-(3-methylpiperidine)-5-nitrobenzoic acid which was hydrogenated over Pd/C to 75% the 5-amino analog II. Gattermann reaction of II gave 47% 5-chloro-3-(2-methylpiperidino) benzoic acid which reacted with N,N'-carbonyldiimidazole in THF to give the imidazolide. Treating this with 4-(H2NCH2CH2)C6H4CO2Me gave 51% benzamide III (R6 = Me), sapon. of which gave 83% III (R6 = H). At 5 mg/kg (rats), III (R = H) lowered blood sugar 44, 42, 38, and 35% after 1, 2, 3, and 4 h, resp.

IT **78253-51-7P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. and sapon. of)

RN 78253-51-7 CAPLUS

CN Benzoic acid, 4-[2-[[5-chloro-2-[methyl(phenylmethyl)amino]benzoyl]amino]ethyl]-, ethyl ester (9CI) (CA INDEX NAME)



IT **78253-52-8P**

RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)
RN 78253-52-8 CAPLUS
CN Benzoic acid, 4-[2-[[5-chloro-2-[methyl(phenylmethyl)amino]benzoyl]amino]ethyl]- (9CI) (CA INDEX NAME)



L31 ANSWER 41 OF 55 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1966:43744 CAPLUS
DOCUMENT NUMBER: 64:43744
ORIGINAL REFERENCE NO.: 64:8153f-h,8154a-b
TITLE: Pyridyl-ethylated anthranilamides
INVENTOR(S): Schipper, Edgar S.
PATENT ASSIGNEE(S): Shulton, Inc.
SOURCE: 5 pp.
DOCUMENT TYPE: Patent
LANGUAGE: Unavailable
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 3226394		19651228	US	19640616

ED Entered STN: 22 Apr 2001
GI For diagram(s), see printed CA Issue.
AB The title compds., which show central nervous system depressant activity in animals, were produced by treating equimolar amts. of a vinylpyridine with an anthranilamide. Thus, a mixt. of 0.1M anthranilamide, 0.1M .omicron.-vinylpyridine, 0.1M AcOH, and 50 ml. MeOH was refluxed 4-24 hrs., the solvent was evapd. in vacuo, the residue poured into ice and made basic with concd. KOH to give 58% 2-.beta.-(2-pyridyl)ethylaminobenzamide I (Py2 = 2-pyridyl, R1 = R2 = R3 = R4 = H), m. 137-8.degree.. The following I derivs. were similarly prepd. from .beta.-vinylpyridine and the appropriate anthranilamide (Py = 4-pyridyl in all cases. R1, R2, R3, R4, m.p., and % yield given): H, H, H, H, 167-8.degree., 55; H, H, Cl, H, 218-19.degree., 81; H, H, H, Cl, 175-7.degree., 62; H, H, NO2, H, 268-70.degree., 6; Pr, H, H, H, 55-7.degree., 44; cyclopropyl, H, Cl, H, 177-8.degree., 65; homoveratryl, H, Cl, H, 113-14.degree., 15; p-anisyl, H, Cl, H, 144-5.degree., 41; propargyl, H, Cl, H, 191-2.degree., 71; .omicron.-MeC6H4, H, H, H, 124-5.degree., 86; p-ClC6H4, H, H, H, 178-9.degree., 35; allyl, H, H, H, 76-7.degree., 47; propargyl, H, H, H, 116-17.degree., 59; H, MeO, H, H, 188-9.degree., 58; and H, MeO, H, 207-8.degree., 52. The following intermediates (II) were prepd. according to published procedures (Clark and Wagner, CA 38, 20362) from 5-chloroisatoic anhydride or isatoic anhydride and the appropriate amine (R, R', m.p., and % yield given): cyclopropyl, Cl, 151-3.degree., 89; homoveratryl, Cl, 130-2.degree., 71; propargyl, Cl, 117.degree., 67; allyl, H, 92-3.degree., 90; propargyl, H, 98-9.degree., 25. A soln. of 77.5 g. .omicron.-NO2C6H4COCl in 100 ml. dry C6H6 was added dropwise to a stirred soln. of 91 g. .omicron.-toluidine in

200 ml. C6H6 and the mixt. was refluxed 1 hr. and worked up in the usual manner to give 82% 2-nitro-N-o-tolylbenzamide (III), m. 178-9.degree.. A soln. of 66 g. III in 600 ml. EtOH was hydrogenated at 3 atm. in the presence of 5% Pd-C to give 93% II (R = .omicron.-tolyl, R' = H), m. 107-8.degree.. II (R = p-ClC6H4, R' = H), m. 148-50.degree., was similarly obtained in 85% yield from the corresponding nitro compd. A mixt. of 18.5 g. 2-nitro-4,5-dimethoxybenzoic acid and 30 ml. SOCl2 was heated 2 hrs. at 80.degree., dild. with 120 ml. C6H6 and 80 ml. Et2O and the soln. added dropwise to a stirred and cooled soln. of 200 ml. NH4OH. The mixt. was stirred overnight to give 15.5 g. 2-nitro-4,5-dimethoxybenzamide (IV), m. 196-7.degree. (EtOH). A slurry of 7.5 g. IV in 200 ml. EtOH was hydrogenated over Pd-C at 42 lb. to give 4.5 g. 4,5-dimethoxyanthranilamide, m. 143-4.degree..

IT **4943-76-4**, Benzanilide, 4'-chloro-2-[[2-(4-pyridyl)ethyl]amino]- **4959-58-4**, Benzamide, 5-chloro-N-(3,4-dimethoxyphenethyl)-2-[[2-(4-pyridyl)ethyl]amino]- **4959-59-5**, o-Benzotoluidide, 2-[[2-(4-pyridyl)ethyl]amino]- **5004-85-3**, p-Benzanisidide, 5-chloro-2-[[2-(4-pyridyl)ethyl]amino]-
(prepn. of)

RN 4943-76-4 CAPLUS

CN Benzanilide, 4'-chloro-2-[[2-(4-pyridyl)ethyl]amino]- (7CI, 8CI) (CA INDEX NAME)





RN 4959-58-4 CAPLUS

CN Benzamide, 5-chloro-N-(3,4,-dimethoxyphenethyl)-2-[[2-(4-pyridyl)ethyl]amino]- (7CI, 8CI) (CA INDEX NAME)



RN 4959-59-5 CAPLUS

CN o-Benzotoluidide, 2-[[2-(4-pyridyl)ethyl]amino]- (7CI, 8CI) (CA INDEX NAME)





RN 5004-85-3 CAPLUS
CN p-Benzanisidide, 5-chloro-2-[[2-(4-pyridyl)ethyl]amino]- (7CI, 8CI) (CA INDEX NAME)





L31 ANSWER 42 OF 55 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1961:59508 CAPLUS
DOCUMENT NUMBER: 55:59508
ORIGINAL REFERENCE NO.: 55:11421a-c
TITLE: Reaction of halopyruvic acid with thiolamines
AUTHOR(S): Hermann, Peter
CORPORATE SOURCE: Univ. Halle, Germany
SOURCE: Chemische Berichte (1961), 94, 442-5
CODEN: CHBEAM; ISSN: 0009-2940
DOCUMENT TYPE: Journal
LANGUAGE: Unavailable
ED Entered STN: 22 Apr 2001
GI For diagram(s), see printed CA Issue.
AB BrCH2COCO2H (I) with H2N(CH2)2SH (II) yielded III (R = CO2H) (IV). I (5.0 g.) in 20 cc. H2O treated with cooling with 2.3 g. II while being bubbled with N, the pH adjusted with 6N KOH to 7-8, the mixt. kept 15 min., and acidified with 5N HCl yielded 1.8 g. IV, m. 143-4.degree. (decompn.). II (3.5 g.) in 60 cc. dry CHCl3 treated dropwise with cooling and stirring with 6.8 g. I and 7.0 cc. Et3N gave 3.0 g. crude IV. IV (0.5 g.) in 40 cc. H2O refluxed and cooled gave 0.33 g. III (R = H) (V), m. 137-8.degree.. III in MeOH treated with dry HCl and dild. with Et2O gave V.HCl, m. 188.degree. (decompn.). The ultraviolet absorption spectra of IV and 5-carbomethoxy-5,6-dihydro-.DELTA.3,4-1,4-thiazine-3-carboxylic acid were recorded.
IT **85094-67-3**, p-Anisanilide, 2'-(benzylcarbamoyl)thio- (prepn. of)
RN 85094-67-3 CAPLUS
CN Benzamide, 2-[[(4-methoxyphenyl)thioxomethyl]amino]-N-(phenylmethyl)- (9CI) (CA INDEX NAME)



L31 ANSWER 43 OF 55 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1961:59507 CAPLUS
DOCUMENT NUMBER: 55:59507
ORIGINAL REFERENCE NO.: 55:11420f-i,11421a
TITLE: Heterocyclic sulfur compounds. I. Action of primary amines on 3,1-benzothiazine-4-thiones and 3,1-benzothiazin-4-one
AUTHOR(S): Legrand, Louis; Lozac'h, Noel
CORPORATE SOURCE: Fac. sci., Caen
SOURCE: Bulletin de la Societe Chimique de France (1960) 2088-92
CODEN: BSCFAS; ISSN: 0037-8968
DOCUMENT TYPE: Journal
LANGUAGE: Unavailable
ED Entered STN: 22 Apr 2001
AB A satd. alc.-soln. of 3,1-benzothiazine-4-thione and an equimolar quantity of the amine were refluxed until the initial red color changed to pale yellow. After evapg. 3/4 of its vol., the soln. was cooled, and yellow crystals of 3H-quinazoline-4-thione sepd. and was recrystd. from ethanol or ethanol-benzene. For aromatic amines and arylbenzothiazines, the mixt. was heated at 200.degree. without solvent until no more H2S was evolved. The following 3H-quinazoline-4-thiones with an alkyl or aryl substituent in position 2 or 3 of the heterocyclic nucleus were prepd. (substituents and m.p. given): 3-ethyl, 132.degree.; 3-butyl, 61.degree.; 3-benzyl, 110.degree.; 3-phenyl, 125.degree.; 3-(p-tolyl), 121.degree.; 3-(p-methoxyphenyl), 124.5.degree.; 3-(p-sulfamoylphenyl), 256.5.degree.; 2,3-dimethyl, 100.degree.; 2-methyl-3-ethyl, 109.degree.; 2-methyl-3-butyl, 65.degree.; 2-methyl-3-benzyl, 94.5.degree.; 2-methyl-3-phenyl, 186.degree.; 2-methyl-3-(p-methoxyphenyl), 153.degree.; 2-methyl-3-(p-aminophenyl), 212.degree.; 2-methyl-3-(p-sulfamoylphenyl), 267.degree.; 2-methyl-3(2-diethylaminoethyl), - (oil); 2-ethyl-3-methyl, 110.degree.; 2,3-diethyl, 94.degree.; 2-ethyl-3-phenyl, 123.degree.; 2-ethyl-3-(o-tolyl), 122.degree.; 2-isopropyl-3-ethyl, 56.degree.; 2-isopropyl-3-phenyl, 173.degree.; 2-benzyl-3-methyl, 96.degree.; 2-benzyl-3-ethyl, 129.degree.; 2-benzyl-3-phenyl, 156.degree.; 2-phenyl-3-methyl, 149.degree.; 2-phenyl-3-ethyl, 116.degree.; 2-phenyl-3-butyl, 146.degree.; 2-phenyl-3-benzyl, 165.degree.; 2,3-diphenyl, 208.degree.; 2-phenyl-3-(p-tolyl), 228.degree.; 2-phenyl-3-(p-methoxyphenyl), 215.degree.; 2-phenyl-3-(p-sulfamoyphenyl), 285.degree.; 2-(p-tolyl)3-butyl, 135.degree.; 2-(p-tolyl)-3-benzyl, 126.degree.; 2-(p-methoxyphenyl)-3-butyl, 104.degree.; 2-(p-methoxyphenyl)-3-phenyl, 231.degree.; 2-(o-chlorophenyl)-3-benzyl, 114.degree.; 2-(p-chlorophenyl)-3-benzyl, 143.degree.; 2-(p-chlorophenyl)-3-phenyl, 231.degree.; 2-(.alpha.-naphthyl)-3-phenyl, 180.degree..
IT **85094-67-3**, p-Anisanilide, 2'-(benzylcarbamoyl)thio- (prepn. of)
RN 85094-67-3 CAPLUS
CN Benzamide, 2-[[(4-methoxyphenyl)thioxomethyl]amino]-N-(phenylmethyl)- (9CI) (CA INDEX NAME)



L31 ANSWER 44 OF 55 USPATFULL on STN
ACCESSION NUMBER: 2004:51588 USPATFULL
TITLE: Selected anthranilaminde pyridinamides and their use as pharmaceutical agents
INVENTOR(S): Huth, Andreas, Berlin, GERMANY, FEDERAL REPUBLIC OF
Krueger, Martin, Berlin, GERMANY, FEDERAL REPUBLIC OF
Zorn, Ludwig, Berlin, GERMANY, FEDERAL REPUBLIC OF
Ince, Stuart, Berlin, GERMANY, FEDERAL REPUBLIC OF
Thierauch, Karl-Heinz, Berlin, GERMANY, FEDERAL REPUBLIC OF
Menrad, Andreas, Oranienburg, GERMANY, FEDERAL REPUBLIC OF
Haberey, Martin, Berlin, GERMANY, FEDERAL REPUBLIC OF
Hess-Stumpp, Holger, Berlin, GERMANY, FEDERAL REPUBLIC OF
PATENT ASSIGNEE(S): Schering AG, Berlin, GERMANY, FEDERAL REPUBLIC OF (non-U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2004039019	A1	20040226	
APPLICATION INFO.:	US 2003-464853	A1	20030619	(10)

	NUMBER	DATE
PRIORITY INFORMATION:	DE 2002-10228090	20020619
	US 2002-404773P	20020821 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: MILLEN, WHITE, ZELANO & BRANIGAN, P.C., 2200 CLARENDON BLVD., SUITE 1400, ARLINGTON, VA, 22201
NUMBER OF CLAIMS: 10
EXEMPLARY CLAIM: 1
LINE COUNT: 567
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Selected anthranilamide pyridinamines of general formula I ##STR1##

in which R.sup.1 and R.sup.2 have the meanings that are indicated in the description, as VEGFR-2 and VEGFR-3 inhibitors, their production and use as pharmaceutical agents for treating various diseases that are triggered by persistent angiogenesis, are described.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT **643081-97-4P 643081-98-5P**
(prepn. of N-(pyridinylmethyl)anthranilamides as VEGFR-2 and VEGFR-3 inhibitors for treating diseases caused by persistent angiogenesis)
RN 643081-97-4 USPATFULL
CN Benzamide, N-(2,3-dihydro-2-oxo-1H-indol-6-yl)-2-[[(1,6-dihydro-6-oxo-3-pyridinyl)methyl]amino]- (9CI) (CA INDEX NAME)



RN 643081-98-5 USPATFULL
CN Benzamide, N-[1-(cyanomethyl)-1H-indazol-6-yl]-2-[[(1,6-dihydro-6-oxo-3-pyridinyl)methyl]amino]- (9CI) (CA INDEX NAME)



L31 ANSWER 45 OF 55 USPATFULL on STN
ACCESSION NUMBER: 2003:232587 USPATFULL
TITLE: Combination of MTP inhibitors or apoB-secretion inhibitors with fibrates for use as pharmaceuticals
INVENTOR(S): Thomas, Leo, Biberach, GERMANY, FEDERAL REPUBLIC OF
Mark, Michael, Biberach, GERMANY, FEDERAL REPUBLIC OF
PATENT ASSIGNEE(S): Boehringer Ingelheim Pharma KG, Ingelheim, GERMANY, FEDERAL REPUBLIC OF (non-U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2003162788	A1	20030828	
APPLICATION INFO.:	US 2003-339088	A1	20030109	(10)

	NUMBER	DATE	
PRIORITY INFORMATION:	DE 2002-10200633	20020110	
	DE 2002-10256184	20021202	
	US 2002-353397P	20020201	(60)
	US 2002-435386P	20021220	(60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: BOEHRINGER INGELHEIM CORPORATION, 900 RIDGEBURY ROAD, P. O. BOX 368, RIDGEFIELD, CT, 06877
NUMBER OF CLAIMS: 39
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 3 Drawing Page(s)
LINE COUNT: 6288
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention relates to the use of fibrates for lowering the liver

toxicity of MTP inhibitors as well as pharmaceutical compositions containing an MTP inhibitor and a fibrate.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT **486436-62-8P**
(combination of microsomal triglyceride transfer protein inhibitors or apoB secretion inhibitors with fibrates for use as drugs)

RN 486436-62-8 USPATFULL

CN 1H-Pyrrole-2-carboxamide, 1-methyl-N-[(4'-methyl[1,1'-biphenyl]-4-yl)methyl]-4-[[2-[(phenylmethyl)amino]benzoyl]amino]- (9CI) (CA INDEX NAME)



L31 ANSWER 46 OF 55 USPATFULL on STN

ACCESSION NUMBER: 2003:181506 USPATFULL

TITLE: Substituted alkylamine derivatives and methods of use

INVENTOR(S): Chen, Guoqing, Thousand Oaks, CA, UNITED STATES
Adams, Jeffrey, Thousand Oaks, CA, UNITED STATES
Bemis, Jean, Arlington, VA, UNITED STATES
Booker, Shon, Newbury Park, CA, UNITED STATES
Cai, Guolin, Thousand Oaks, CA, UNITED STATES
Pietro, Lucian Di, Gloucester, MA, UNITED STATES
Dominguez, Celia, Thousand Oaks, CA, UNITED STATES
Elbaum, Daniel, Newton, MA, UNITED STATES
Germain, Julie, Somerville, MA, UNITED STATES
Geuns-Meyer, Stephanie, Medford, MA, UNITED STATES
Handley, Michael, Ventura, CA, UNITED STATES
Huang, Qi, Moorpark, CA, UNITED STATES
Kim, Joseph L., Wayland, MA, UNITED STATES
Kim, Tae-Seong, Thousand Oaks, CA, UNITED STATES
Kiselyov, Alexander, Jersey City, NJ, UNITED STATES
Ouyang, Xiaohu, Flushing, NY, UNITED STATES
Patel, Vinod F., Acton, MA, UNITED STATES
Smith, Leon M., Somerset, NJ, UNITED STATES
Stec, Markian, Filmore, CA, UNITED STATES
Tasker, Andrew, Simi Valley, CA, UNITED STATES
Xi, Ning, Thousand Oaks, CA, UNITED STATES
Xu, Shimin, Newbury Park, CA, UNITED STATES
Yuan, Chester Chenguang, Newbury Park, CA, UNITED STATES
Croghan, Michael, Ventura, CA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003125339	A1	20030703

APPLICATION INFO.: US 2002-46681 A1 20020110 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-261339P	20010112 (60)
	US 2001-323764P	20010919 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: U.S. Patent Operations/JWB, Dept. 4300, M/S 27-4-A, AMGEN INC., One Amgen Center Drive, Thousand Oaks, CA, 91320-1799
NUMBER OF CLAIMS: 62
EXEMPLARY CLAIM: 1
LINE COUNT: 11080
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Selected heterocyclic compounds are effective for prophylaxis and treatment of diseases, such as angiogenesis mediated diseases. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable derivatives thereof, pharmaceutical compositions and methods for prophylaxis and treatment of diseases and other maladies or conditions involving, cancer and the like. The subject invention also relates to processes for making such compounds as well as to intermediates useful in such processes.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT **453564-10-8P**
(prepn. of heterocyclylalkylamine derivs. as remedies for angiogenesis mediated diseases)
RN 453564-10-8 USPATFULL
CN Benzamide, N-(2-acetyl-1,2,3,4-tetrahydro-4,4-dimethyl-7-isoquinolinyl)-2-[(4-quinolinylmethyl)amino]- (9CI) (CA INDEX NAME)



L31 ANSWER 47 OF 55 USPATFULL on STN
ACCESSION NUMBER: 2003:106923 USPATFULL
TITLE: Heteroarylcarboxylic acid amides, the preparation thereof and their use as pharmaceutical compositions
INVENTOR(S): Priepke, Henning, Warthausen, GERMANY, FEDERAL REPUBLIC OF
Hauel, Norbert, Schemmerhofen, GERMANY, FEDERAL REPUBLIC OF
Dahmann, Georg, Attenweiler, GERMANY, FEDERAL REPUBLIC OF
Thomas, Leo, Biberach, GERMANY, FEDERAL REPUBLIC OF
Mark, Michael, Biberach, GERMANY, FEDERAL REPUBLIC OF

PATENT ASSIGNEE(S): Boehringer Ingelheim Pharma KG, Ingelheim, GERMANY, FEDERAL REPUBLIC OF (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003073836	A1	20030417
APPLICATION INFO.:	US 2002-187860	A1	20020702 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	DE 2001-DE132686	20010711
	US 2001-304584P	20010711 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: BOEHRINGER INGELHEIM CORPORATION, 900 RIDGEBURY ROAD, P. O. BOX 368, RIDGEFIELD, CT, 06877
NUMBER OF CLAIMS: 24
EXEMPLARY CLAIM: 1
LINE COUNT: 4375
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A compound of formula ##STR1##

wherein: A.sup.a, R.sup.a, X.sub.1 to X.sub.4, Het, and R.sup.5 to R.sup.7 are defined as in claim 1, the isomers and the salts thereof, particularly the physiologically acceptable salts thereof, which are valuable inhibitors of the microsomal triglyceride-transfer protein (MTP), medicaments containing these compounds and their use, as well as the preparation thereof.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT **486436-62-8P**
(drug candidate; prepn. of biphenylcarboxylic acid amides as microsomal triglyceride transfer protein (MTP) inhibitors)
RN 486436-62-8 USPATFULL
CN 1H-Pyrrole-2-carboxamide, 1-methyl-N-[(4'-methyl[1,1'-biphenyl]-4-yl)methyl]-4-[[2-[(phenylmethyl)amino]benzoyl]amino]- (9CI) (CA INDEX NAME)



L31 ANSWER 48 OF 55 USPATFULL on STN
ACCESSION NUMBER: 2003:93631 USPATFULL
TITLE: N-aryl (thio) anthranilic acid amide derivatives, their preparation and their use as VEGF receptor tyrosine kinase inhibitors
INVENTOR(S): Altmann, Karl-Heinz, Reinach, SWITZERLAND

Bold, Guido, Gipf-Oberfrick, SWITZERLAND
Furet, Pascal, Thann, FRANCE
Manley, Paul William, Arlesheim, SWITZERLAND
Wood, Jeanette Marjorie, Biel-Benken, SWITZERLAND
Ferrari, Stefano, Muttenz, SWITZERLAND
Hofmann, Francesco, Bottmingen, SWITZERLAND
Mestan, Jurgen, Denzlingen, GERMANY, FEDERAL REPUBLIC OF
Huth, Andreas, Berlin, GERMANY, FEDERAL REPUBLIC OF
Kruger, Martin, Berlin, GERMANY, FEDERAL REPUBLIC OF
Seidelmann, Dieter, Berlin, GERMANY, FEDERAL REPUBLIC OF
Menrad, Andreas, Oranienburg, GERMANY, FEDERAL REPUBLIC OF
Haberey, Martin, Berlin, GERMANY, FEDERAL REPUBLIC OF
Thierauch, Karl-Heinz, Berlin, GERMANY, FEDERAL REPUBLIC OF

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003064992	A1	20030403
APPLICATION INFO.:	US 2002-180289	A1	20020626 (10)

RELATED APPLN. INFO.: Division of Ser. No. US 2001-850434, filed on 7 May 2001, GRANTED, Pat. No. US 6448277 A 371 of International Ser. No. WO 1999-EP8545, filed on 8 Nov 1999, UNKNOWN

	NUMBER	DATE
PRIORITY INFORMATION:	GB 1998-24579	19981110

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: THOMAS HOXIE, NOVARTIS CORPORATION, PATENT AND TRADEMARK DEPT, 564 MORRIS AVENUE, SUMMIT, NJ, 079011027
NUMBER OF CLAIMS: 17
EXEMPLARY CLAIM: 1
LINE COUNT: 2632
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB ##STR1##

Described are compunds of formula (I), wherein W is O or S; X is NR.sub.8; Y is CR.sub.9R.sub.10--(CH.sub.2)n wherein R.sub.9 and R.sub.10 are independently of each other hydrogen or lower alkyl, and n is an integer of from and including 0 to and including 3; or Y is SO.sub.2; R.sub.1 is aryl; R.sub.2 is a mono- or bicyclic heteroaryl group comprising one or more ring nitrogen atoms with the exception that R.sub.2 cannot represent 2-phthalimidyl, and in case of Y=SO.sub.2 cannot represent 2,1,3-benzothiadiazol-4-yl; any of R.sub.3, R.sub.4, R.sub.5 and R.sub.6, independently of the other, is H or a substituent other than hydrogen; and R.sub.7 and R.sub.8, independently of each other, are H or lower alkyl; or a N-oxide or a pharmaceutically acceptable salt thereof for the preparation of a pharmaceutical product for the treatment of a neoplastic disease which responds to an inhibition of the VEGF receptor tyrosine kinase activity. The compounds of formula (I) can be used for the treatment e.g. of a neoplastic disease, such as a tumor disease, of retinopathy and age-related macular degeneration.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT **267891-62-3P**
(prepn. of anthranilic acid amides as VEGF receptor inhibitors)
RN 267891-62-3 USPATFULL

CN Benzamide, N-[2-(4-chlorophenyl)ethyl]-2-[[(4-methoxyphenyl)methyl]amino]- (9CI) (CA INDEX NAME)



IT **267891-04-3P 267891-05-4P 267891-06-5P**
267891-07-6P 267891-09-8P 267891-10-1P
267891-11-2P 267891-12-3P 267891-13-4P
267891-14-5P 267891-15-6P 267891-16-7P
267891-17-8P 267891-18-9P 267891-19-0P
267891-20-3P 267891-21-4P 267891-22-5P
267891-23-6P 267891-24-7P 267891-25-8P
267891-26-9P 267891-27-0P 267891-28-1P
267891-29-2P 267891-30-5P 267891-31-6P
267891-32-7P 267891-33-8P 267891-34-9P
267891-35-0P 267891-36-1P 267891-37-2P
267891-38-3P 267891-39-4P 267891-40-7P
267891-41-8P 267891-42-9P 267891-43-0P
267891-44-1P 267891-45-2P 267891-46-3P
267891-47-4P 267891-48-5P 267891-49-6P
267891-50-9P 267891-51-0P 267891-52-1P
267891-53-2P 267891-54-3P 267891-55-4P
267891-56-5P 267891-57-6P 267891-58-7P
267891-59-8P 267891-61-2P 267891-63-4P
267891-64-5P 267891-65-6P 267891-66-7P
267891-67-8P 267891-68-9P 267891-69-0P
267891-70-3P 267891-72-5P 267891-73-6P
267891-74-7P 267891-75-8P 267891-76-9P
267891-77-0P 267891-78-1P 267891-79-2P
267891-80-5P 267891-81-6P 267891-82-7P
267891-83-8P 267891-84-9P 267891-85-0P
(prepn. of anthranilic acid amides as VEGF receptor inhibitors)

RN 267891-04-3 USPATFULL

CN Benzamide, N-(3-phenylpropyl)-2-[(4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)



RN 267891-05-4 USPATFULL

CN Benzamide, N-[(4-chlorophenyl)methyl]-2-[(4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)



RN 267891-06-5 USPATFULL
CN Benzamide, N-(2,3-dihydro-1H-inden-2-yl)-2-[(4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)



RN 267891-07-6 USPATFULL
CN Benzamide, N-[2-(4-chlorophenyl)ethyl]-2-[(4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)



RN 267891-09-8 USPATFULL
CN Benzamide, 2-[(4-pyridinylmethyl)amino]-N-(2-thienylmethyl)- (9CI) (CA INDEX NAME)



RN 267891-10-1 USPATFULL
CN Benzamide, N-(1,1-dimethyl-2-phenylethyl)-2-[(4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)



RN 267891-11-2 USPATFULL
CN Benzamide, N-[2-(6-fluoro-1H-indol-3-yl)ethyl]-2-[(4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)



RN 267891-12-3 USPATFULL
CN Benzamide, 2-[(4-pyridinylmethyl)amino]-N-(1,2,3,4-tetrahydro-6,7-dimethoxy-2-naphthalenyl)- (9CI) (CA INDEX NAME)



RN 267891-13-4 USPATFULL
CN Benzamide, N-(1-naphthalenylmethyl)-2-[(4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)



RN 267891-14-5 USPATFULL

CN Benzamide, N-[1-(1-naphthalenyl)ethyl]-2-[(4-pyridinylmethyl)amino]-. (9CI) (CA INDEX NAME)



RN 267891-15-6 USPATFULL
CN Benzamide, 2-[(4-pyridinylmethyl)amino]-N-(1,2,3,4-tetrahydro-1-naphthalenyl)- (9CI) (CA INDEX NAME)



RN 267891-16-7 USPATFULL
CN Benzamide, N-[1-(4-chlorophenyl)ethyl]-2-[(4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)



RN 267891-17-8 USPATFULL
CN Benzamide, N-[2-(4-chlorophenyl)-1-methylethyl]-2-[(4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)



RN 267891-18-9 USPATFULL
CN Benzamide, N-(1-methyl-1-phenylethyl)-2-[(4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)



RN 267891-19-0 USPATFULL
CN Benzamide, 2-[(4-pyridinylmethyl)amino]-N-5-quinolinyl- (9CI) (CA INDEX NAME)



RN 267891-20-3 USPATFULL
CN Benzamide, 2-[(4-pyridinylmethyl)amino]-N-3-quinolinyl- (9CI) (CA INDEX NAME)



RN 267891-21-4 USPATFULL
CN Benzamide, N-[2-(3-pyridinyl)ethyl]-2-[(4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)



RN 267891-22-5 USPATFULL
CN Benzamide, N-[2-(4-pyridinyl)ethyl]-2-[(4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)



RN 267891-23-6 USPATFULL
CN Benzamide, N-1-isoquinolinyl-2-[(4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)



RN 267891-24-7 USPATFULL
CN Benzamide, N-(5-chloro-2-pyrimidinyl)-2-[(4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)



RN 267891-25-8 USPATFULL
CN Benzamide, N-[1-[(1-bromo-3-isoquinolinyl)amino]-3-isoquinolinyl]-2-[(4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)



FRAGMENT DIAGRAM IS INCOMPLETE

RN 267891-26-9 USPATFULL
CN Benzamide, 2-[(4-pyridinylmethyl)amino]-N-8-quinolinyl- (9CI) (CA INDEX NAME)



RN 267891-27-0 USPATFULL
CN Benzamide, N-[2-(4-methoxyphenyl)ethyl]-2-[(4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)



RN 267891-28-1 USPATFULL
CN Benzamide, N-[2-(4-hydroxyphenyl)ethyl]-2-[(4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)



RN 267891-29-2 USPATFULL
CN Benzamide, N-2-pyridinyl-2-[(4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)





RN 267891-30-5 USPATFULL
CN Benzamide, N-(3-pyridinylmethyl)-2-[(4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)



RN 267891-31-6 USPATFULL
CN Benzamide, N-(5-chloro-2-pyridinyl)-2-[(4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)





RN 267891-32-7 USPATFULL
CN Benzamide, N-3-pyridinyl-2-[(4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)





RN 267891-33-8 USPATFULL
CN Benzamide, 2-[(4-pyridinylmethyl)amino]-N-[5-(trifluoromethyl)-1,3,4-thiadiazol-2-yl]- (9CI) (CA INDEX NAME)



RN 267891-34-9 USPATFULL
CN Benzamide, 2-[(4-pyridinylmethyl)amino]-N-[[4-(trifluoromethyl)phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 267891-35-0 USPATFULL
CN Benzamide, N-(5-phenyl-1H-pyrazol-3-yl)-2-[(4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)



RN 267891-36-1 USPATFULL
CN Benzamide, N-(trans-4-phenylcyclohexyl)-2-[(4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 267891-37-2 USPATFULL
CN Benzamide, N-(1-isoquinolinylmethyl)-2-[(4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)



RN 267891-38-3 USPATFULL
CN Benzamide, 2-[(4-pyridinylmethyl)amino]-N-(2-quinolinylmethyl)- (9CI) (CA INDEX NAME)



RN 267891-39-4 USPATFULL
CN Benzamide, 2-[(4-pyridinylmethyl)amino]-N-(1,2,3,4-tetrahydro-7-quinolinyl)- (9CI) (CA INDEX NAME)



RN 267891-40-7 USPATFULL
CN Benzamide, N-(2-phenylcyclohexyl)-2-[(4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)



RN 267891-41-8 USPATFULL
CN Benzamide, N-(2,3-dihydro-1,4-benzodioxin-6-yl)-2-[(4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)



RN 267891-42-9 USPATFULL
CN Benzamide, 2-[(4-pyridinylmethyl)amino]-N-6-quinolinyl- (9CI) (CA INDEX NAME)



RN 267891-43-0 USPATFULL
CN Benzamide, 2-[(4-pyridinylmethyl)amino]-N-2-quinolinyl- (9CI) (CA INDEX NAME)



RN 267891-44-1 USPATFULL
CN Benzamide, N-3-isoquinolinyl-2-[(4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)



RN 267891-45-2 USPATFULL
CN Benzamide, N-1H-indol-5-yl-2-[(4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)



RN 267891-46-3 USPATFULL
CN Benzamide, N-(3-methyl-2-quinolinyl)-2-[(4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)



RN 267891-47-4 USPATFULL
CN Benzamide, N-(6-chloro-3-methyl-2-quinolinyl)-2-[(4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)



RN 267891-48-5 USPATFULL
CN Benzamide, N-(7-chloro-3-methyl-2-quinolinyl)-2-[(4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)



RN 267891-49-6 USPATFULL
CN Benzamide, N-(6-fluoro-3-methyl-2-quinolinyl)-2-[(4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)



RN 267891-50-9 USPATFULL
CN Benzamide, N-(7-fluoro-3-methyl-2-quinolinyl)-2-[(4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)



RN 267891-51-0 USPATFULL
CN Benzamide, N-(6-methoxy-3-methyl-2-quinolinyl)-2-[(4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)



RN 267891-52-1 USPATFULL
CN Benzamide, N-(7-methoxy-3-methyl-2-quinolinyl)-2-[(4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)



RN 267891-53-2 USPATFULL
CN Benzamide, N-(5-chloro-2-quinazolinyl)-2-[(4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)



RN 267891-54-3 USPATFULL
CN Benzamide, 2-chloro-N-[(4-chlorophenyl)methyl]-6-[(4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)



RN 267891-55-4 USPATFULL
CN Benzamide, 2-chloro-6-[(4-pyridinylmethyl)amino]-N-2-quinolinyl- (9CI) (CA INDEX NAME)



RN 267891-56-5 USPATFULL
CN Benzamide, 5-chloro-2-[(4-pyridinylmethyl)amino]-N-2-quinolinyl- (9CI) (CA INDEX NAME)



RN 267891-57-6 USPATFULL
CN Benzamide, 4-fluoro-N-3-isoquinolinyl-2-[(4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)



RN 267891-58-7 USPATFULL
CN Benzamide, 4-chloro-2-[(4-pyridinylmethyl)amino]-N-2-quinolinyl- (9CI) (CA INDEX NAME)



RN 267891-59-8 USPATFULL
CN Benzamide, 4,5-difluoro-N-3-isoquinolinyl-2-[(4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)



RN 267891-61-2 USPATFULL
CN Benzamide, N-[(4-methoxyphenyl)methyl]-2-[[(4-methoxyphenyl)methyl]amino]- (9CI) (CA INDEX NAME)



RN 267891-63-4 USPATFULL
CN Benzamide, N-[2-(4-chlorophenyl)ethyl]-2-[[(4-hydroxyphenyl)methyl]amino]- (9CI) (CA INDEX NAME)



RN 267891-64-5 USPATFULL
CN Benzamide, 2-[[(1,6-dihydro-6-oxo-3-pyridinyl)methyl]amino]-N-3-isoquinolinyl- (9CI) (CA INDEX NAME)



RN 267891-65-6 USPATFULL
CN Benzamide, N-3-isoquinolinyl-2-[(4-pyrimidinylmethyl)amino]- (9CI) (CA INDEX NAME)



RN 267891-66-7 USPATFULL
CN Benzamide, 5-fluoro-N-3-isoquinolinyl-2-[(4-pyrimidinylmethyl)amino]- (9CI) (CA INDEX NAME)



RN 267891-67-8 USPATFULL
CN Benzamide, 4-fluoro-N-1H-indazol-5-yl-2-[(4-pyrimidinylmethyl)amino]- (9CI) (CA INDEX NAME)



RN 267891-68-9 USPATFULL
CN Benzamide, N-1H-indazol-5-yl-2-[(4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)



RN 267891-69-0 USPATFULL
CN Benzamide, N-1H-benzimidazol-2-yl-2-[(4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)



RN 267891-70-3 USPATFULL
CN Benzamide, N-6-benzothiazolyl-5-fluoro-2-[(4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)



RN 267891-72-5 USPATFULL
CN Benzamide, N-(5,6-dimethyl-1H-benzimidazol-2-yl)-2-[(4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)



RN 267891-73-6 USPATFULL
CN Benzamide, N-6-benzothiazolyl-2-[(4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)



RN 267891-74-7 USPATFULL
CN Benzamide, 2-[(4-pyridinylmethyl)amino]-N-[6-(trifluoromethoxy)-2-benzothiazolyl]- (9CI) (CA INDEX NAME)



RN 267891-75-8 USPATFULL
CN Benzamide, N-1H-indazol-6-yl-2-[(4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)



RN 267891-76-9 USPATFULL
CN Benzamide, N-4-pyridinyl-2-[(4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)



RN 267891-77-0 USPATFULL
CN Benzamide, N-(1-methyl-1H-benzimidazol-2-yl)-2-[(4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)



RN 267891-78-1 USPATFULL
CN Benzamide, N-(6-chloro-2-benzothiazolyl)-2-[(4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)



RN 267891-79-2 USPATFULL
CN Benzamide, N-1H-benzimidazol-5-yl-2-[(4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)



RN 267891-80-5 USPATFULL
CN Benzamide, N-(6-fluoro-2-benzothiazolyl)-2-[(4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)



RN 267891-81-6 USPATFULL
CN Benzamide, N-2-benzothiazolyl-5-chloro-2-[(4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)



RN 267891-82-7 USPATFULL
CN Benzamide, 5-fluoro-N-1H-indazol-5-yl-2-[(4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)



RN 267891-83-8 USPATFULL
CN Benzamide, 5-chloro-N-1H-indazol-5-yl-2-[(4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)



RN 267891-84-9 USPATFULL
CN Benzamide, N-2-benzothiazolyl-5-fluoro-2-[(4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)



RN 267891-85-0 USPATFULL
CN Benzamide, N-6-benzothiazolyl-5-chloro-2-[(4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)



IT **267891-92-9 267891-93-0 267891-94-1**
267891-95-2 267891-96-3 267891-97-4
267891-98-5 267891-99-6 267892-01-3
267892-02-4 267892-03-5 267892-04-6
267892-05-7 267892-06-8 267892-07-9

267892-09-1 267892-11-5 267892-14-8
267892-15-9
(prepn. of anthranilic acid amides as VEGF receptor inhibitors)

RN 267891-92-9 USPATFULL
CN Benzamide, N-(4-pyridinylmethyl)-2-[(4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)



RN 267891-93-0 USPATFULL
CN Benzamide, N-[3-(4-chlorophenyl)propyl]-2-[(4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)



RN 267891-94-1 USPATFULL
CN Benzamide, N-[2-(4-chlorophenyl)propyl]-2-[(4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)



RN 267891-95-2 USPATFULL
CN Benzamide, N-(2-phenylpropyl)-2-[(4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)



RN 267891-96-3 USPATFULL
CN Benzamide, N-(5-chloro-2,3-dihydro-1H-inden-1-yl)-2-[(4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)



RN 267891-97-4 USPATFULL
CN Benzamide, N-[2-(3,4-dimethoxyphenyl)ethyl]-2-[(4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)



RN 267891-98-5 USPATFULL
CN Benzamide, N-2,1,3-benzothiadiazol-5-yl-2-[(4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)



RN 267891-99-6 USPATFULL
CN Benzamide, 2-[(4-pyridinylmethyl)amino]-N-[(1R)-1,2,3,4-tetrahydro-1-naphthalenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 267892-01-3 USPATFULL
CN Benzamide, N-(4-phenylbutyl)-2-[(4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)



RN 267892-02-4 USPATFULL
CN Benzamide, 2-[(4-pyridinylmethyl)amino]-N-[(1S)-1,2,3,4-tetrahydro-1-naphthalenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 267892-03-5 USPATFULL
CN Benzamide, N-(2-phenylethyl)-2-[(4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)



RN 267892-04-6 USPATFULL
CN Benzamide, N-5-isoquinolinyl-2-[(4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)



RN 267892-05-7 USPATFULL
CN Benzamide, N-methyl-N-(2-phenylethyl)-2-[(4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)



RN 267892-06-8 USPATFULL
CN Benzamide, 5-chloro-N-[(4-chlorophenyl)methyl]-2-[(4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)



RN 267892-07-9 USPATFULL
CN Benzamide, 5-chloro-N-(3-phenylpropyl)-2-[(4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)



RN 267892-09-1 USPATFULL
CN Benzamide, 5-fluoro-N-3-isoquinolinyl-2-[(4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)



RN 267892-11-5 USPATFULL
CN Benzamide, 5-chloro-N-3-isoquinolinyl-2-[(4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)



RN 267892-14-8 USPATFULL
CN Benzamide, N-2-benzothiazolyl-4-fluoro-2-[(4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)



RN 267892-15-9 USPATFULL
CN Benzamide, N-(4-chloro-2-benzothiazolyl)-2-[(4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)



IT **267891-90-7**
(prepn. of anthranilic acid amides as VEGF receptor inhibitors)
RN 267891-90-7 USPATFULL
CN Benzamide, 2-[[(1,2-dihydro-2-oxo-4-pyridinyl)methyl]amino]-N-3-isoquinolinyl- (9CI) (CA INDEX NAME)



L31 ANSWER 49 OF 55 USPATFULL on STN

ACCESSION NUMBER:	2002:338243 USPATFULL
TITLE:	Anthranilic acid derivatives as inhibitors of the CGMP-phosphodiesterase
INVENTOR(S):	Oku, Teruo, Tokyo, JAPAN Oku, Noriko, Tokyo, JAPAN LR Oku, Chikako, Tokyo, JAPAN LR Oku, Tomohito, Tokyo, JAPAN LR Sawada, Kozo, Tsukuba-shi, JAPAN Kuroda, Akio, Tsukuba-shi, JAPAN Inoue, Takayuki, Tsukuba-shi, JAPAN Kayakiri, Natsuko, Osaka, JAPAN Sawada, Yuki, Ushiku-shi, JAPAN Mizutani, Tsuyoshi, Tsukuba-shi, JAPAN
PATENT ASSIGNEE(S):	Fujisawa Pharmaceutical Co. Ltd., Osaka-shi, JAPAN, 541-8514 (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002193614	A1	20021219
APPLICATION INFO.:	US 2002-50789	A1	20020118 (10)

RELATED APPLN. INFO.: Continuation of Ser. No. US 2001-509541, filed on 23 Apr 2001, GRANTED, Pat. No. US 6384080

PRIORITY INFORMATION:	NUMBER	DATE
	AU 1998-3085	19980420
	AU 1998-5851	19980911
	AU 1998-7781	19981218
	WO 1999-JP2028	19990415

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION

LEGAL REPRESENTATIVE: OBLON SPIVAK MCCLELLAND MAIER & NEUSTADT PC, FOURTH FLOOR, 1755 JEFFERSON DAVIS HIGHWAY, ARLINGTON, VA, 22202
NUMBER OF CLAIMS: 17
EXEMPLARY CLAIM: 1
LINE COUNT: 5983
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Novel anthranilic acid derivatives having an inhibiting activity of cGMP-PDE are represented by the formula I where A is a lower alkylene group: ##STR1##

The anthranilic acid derivatives show pharmacological activity and may be used in pharmaceutical compositions as medications. The anthranilic acid derivatives can be formed by the reaction of a fluoro precursor with an amine. Pharmaceutical compositions containing the anthranilic acid derivatives can be used to treat or prevent human health disorders.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT **247569-27-3P 247570-30-5P**
(prepn. of anthranilamides as of cGMP-phosphodiesterase inhibitors)
RN 247569-27-3 USPATFULL
CN Benzamide, 5-cyano-N-[(3,4-dimethoxyphenyl)methyl]-2-[[(1S)-2-(1H-imidazol-1-yl)-1-methylethyl]amino]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 247570-30-5 USPATFULL
CN Benzamide, 5-cyano-N-[(3,4-dimethoxyphenyl)methyl]-2-[[(1S)-1-methyl-2-(2-methyl-1H-imidazol-1-yl)ethyl]amino]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

L31 ANSWER 50 OF 55 USPATFULL on STN

ACCESSION NUMBER: 2002:32592 USPATFULL

TITLE: N-aryl(thio)anthranilic acid amide derivatives, their preparation and their use as VEGF receptor tyrosine kinase inhibitors

INVENTOR(S): Altmann, Karl-Heinz, Reinach, SWITZERLAND
Bold, Guido, Gipf-Oberfrick, SWITZERLAND
Furet, Pascal, Thann, FRANCE
Manley, Paul William, Arlesheim, SWITZERLAND
Wood, Jeanette Marjorie, Biel-Benken, SWITZERLAND
Ferrari, Stefano, Muttenz, SWITZERLAND
Hofmann, Francesco, Bottmingen, SWITZERLAND
Mestan, Jurgen, Denzlingen, GERMANY, FEDERAL REPUBLIC OF
Huth, Andreas, Berlin, GERMANY, FEDERAL REPUBLIC OF
Kruger, Martin, Berlin, GERMANY, FEDERAL REPUBLIC OF
Seidelmann, Dieter, Berlin, GERMANY, FEDERAL REPUBLIC OF
Menrad, Andreas, Oranienburg, GERMANY, FEDERAL REPUBLIC OF
Haberey, Martin, Berlin, GERMANY, FEDERAL REPUBLIC OF
Thierauch, Karl-Heinz, Berlin, GERMANY, FEDERAL REPUBLIC OF

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002019414	A1	20020214
	US 6448277	B2	20020910
APPLICATION INFO.:	US 2001-850434	A1	20010507 (9)

RELATED APPLN. INFO.: Continuation of Ser. No. WO 1999-EP8545, filed on 8 Nov 1999, UNKNOWN

	NUMBER	DATE
PRIORITY INFORMATION:	GB 1998-24579	19981110

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: THOMAS HOXIE, NOVARTIS CORPORATION, PATENT AND TRADEMARK DEPT, 564 MORRIS AVENUE, SUMMIT, NJ,

079011027
NUMBER OF CLAIMS: 17
EXEMPLARY CLAIM: 1
LINE COUNT: 2620
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB ##STR1##

Described are compounds of formula (I), wherein W is O or S; X is NR.sub.8; Y is CR.sub.9R.sub.10-(CH.sub.2)n wherein R.sub.9 and R.sub.10 are independently of each other hydrogen or lower alkyl, and n is an integer of from and including 0 to and including 3; or Y is SO.sub.2; R.sub.1 is aryl; R.sub.2 is a mono- or bicyclic heteroaryl group comprising one or more ring nitrogen atoms with the exception that R.sub.2 cannot represent 2-phthalimidyl, and in case of Y.dbd.SO.sub.2 cannot represent 2,1,3-benzothiadiazol-4-yl; any of R.sub.3, R.sub.4, R.sub.5 and R.sub.6, independently of the other, is H or a substituent other than hydrogen; and R.sub.7 and R.sub.8, independently of each other, are H or lower alkyl; or a N-oxide or a pharmaceutically acceptable salt thereof for the preparation of a pharmaceutical product for the treatment of a neoplastic disease which responds to an inhibition of the VEGF receptor tyrosine kinase activity. The compounds of formula (I) can be used for the treatment e.g. of a neoplastic disease, such as a tumor disease, of retinopathy and age-related macular degeneration.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT **267891-62-3P**
(prepn. of anthranilic acid amides as VEGF receptor inhibitors)
RN 267891-62-3 USPATFULL
CN Benzamide, N-[2-(4-chlorophenyl)ethyl]-2-[[(4-methoxyphenyl)methyl]amino]-(9CI) (CA INDEX NAME)



IT **267891-04-3P 267891-05-4P 267891-06-5P**
267891-07-6P 267891-09-8P 267891-10-1P
267891-11-2P 267891-12-3P 267891-13-4P
267891-14-5P 267891-15-6P 267891-16-7P
267891-17-8P 267891-18-9P 267891-19-0P
267891-20-3P 267891-21-4P 267891-22-5P
267891-23-6P 267891-24-7P 267891-25-8P
267891-26-9P 267891-27-0P 267891-28-1P
267891-29-2P 267891-30-5P 267891-31-6P
267891-32-7P 267891-33-8P 267891-34-9P
267891-35-0P 267891-36-1P 267891-37-2P
267891-38-3P 267891-39-4P 267891-40-7P
267891-41-8P 267891-42-9P 267891-43-0P
267891-44-1P 267891-45-2P 267891-46-3P
267891-47-4P 267891-48-5P 267891-49-6P
267891-50-9P 267891-51-0P 267891-52-1P
267891-53-2P 267891-54-3P 267891-55-4P

267891-56-5P 267891-57-6P 267891-58-7P
267891-59-8P 267891-61-2P 267891-63-4P
267891-64-5P 267891-65-6P 267891-66-7P
267891-67-8P 267891-68-9P 267891-69-0P
267891-70-3P 267891-72-5P 267891-73-6P
267891-74-7P 267891-75-8P 267891-76-9P
267891-77-0P 267891-78-1P 267891-79-2P
267891-80-5P 267891-81-6P 267891-82-7P
267891-83-8P 267891-84-9P 267891-85-0P
(prepn. of anthranilic acid amides as VEGF receptor inhibitors)

RN 267891-04-3 USPATFULL
CN Benzamide, N-(3-phenylpropyl)-2-[(4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)



RN 267891-05-4 USPATFULL
CN Benzamide, N-[(4-chlorophenyl)methyl]-2-[(4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)



RN 267891-06-5 USPATFULL
CN Benzamide, N-(2,3-dihydro-1H-inden-2-yl)-2-[(4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)



RN 267891-07-6 USPATFULL
CN Benzamide, N-[2-(4-chlorophenyl)ethyl]-2-[(4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)



RN 267891-09-8 USPATFULL
CN Benzamide, 2-[(4-pyridinylmethyl)amino]-N-(2-thienylmethyl)- (9CI) (CA INDEX NAME)



RN 267891-10-1 USPATFULL
CN Benzamide, N-(1,1-dimethyl-2-phenylethyl)-2-[(4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)



RN 267891-11-2 USPATFULL
CN Benzamide, N-[2-(6-fluoro-1H-indol-3-yl)ethyl]-2-[(4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)



RN 267891-12-3 USPATFULL
CN Benzamide, 2-[(4-pyridinylmethyl)amino]-N-(1,2,3,4-tetrahydro-6,7-dimethoxy-2-naphthalenyl)- (9CI) (CA INDEX NAME)



RN 267891-13-4 USPATFULL
CN Benzamide, N-(1-naphthalenylmethyl)-2-[(4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)



RN 267891-14-5 USPATFULL
CN Benzamide, N-[1-(1-naphthalenyl)ethyl]-2-[(4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)



RN 267891-15-6 USPATFULL
CN Benzamide, 2-[(4-pyridinylmethyl)amino]-N-(1,2,3,4-tetrahydro-1-naphthalenyl)- (9CI) (CA INDEX NAME)



RN 267891-16-7 USPATFULL
CN Benzamide, N-[1-(4-chlorophenyl)ethyl]-2-[(4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)



RN 267891-17-8 USPATFULL
CN Benzamide, N-[2-(4-chlorophenyl)-1-methylethyl]-2-[(4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)



RN 267891-18-9 USPATFULL
CN Benzamide, N-(1-methyl-1-phenylethyl)-2-[(4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)



RN 267891-19-0 USPATFULL
CN Benzamide, 2-[(4-pyridinylmethyl)amino]-N-5-quinolinyl- (9CI) (CA INDEX

NAME)



RN 267891-20-3 USPATFULL
CN Benzamide, 2-[(4-pyridinylmethyl)amino]-N-3-quinolinyl- (9CI) (CA INDEX NAME)



RN 267891-21-4 USPATFULL
CN Benzamide, N-[2-(3-pyridinyl)ethyl]-2-[(4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)



RN 267891-22-5 USPATFULL
CN Benzamide, N-[2-(4-pyridinyl)ethyl]-2-[(4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)



RN 267891-23-6 USPATFULL
CN Benzamide, N-1-isoquinolinyl-2-[(4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)



RN 267891-24-7 USPATFULL
CN Benzamide, N-(5-chloro-2-pyrimidinyl)-2-[(4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)



RN 267891-25-8 USPATFULL
CN Benzamide, N-[1-[(1-bromo-3-isoquinolinyl)amino]-3-isoquinolinyl]-2-[(4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)



FRAGMENT DIAGRAM IS INCOMPLETE

RN 267891-26-9 USPATFULL
CN Benzamide, 2-[(4-pyridinylmethyl)amino]-N-8-quinolinyl- (9CI) (CA INDEX NAME)



RN 267891-27-0 USPATFULL
CN Benzamide, N-[2-(4-methoxyphenyl)ethyl]-2-[(4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)



RN 267891-28-1 USPATFULL
CN Benzamide, N-[2-(4-hydroxyphenyl)ethyl]-2-[(4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)



RN 267891-29-2 USPATFULL
CN Benzamide, N-2-pyridinyl-2-[(4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)





RN 267891-30-5 USPATFULL
CN Benzamide, N-(3-pyridinylmethyl)-2-[(4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)



RN 267891-31-6 USPATFULL
CN Benzamide, N-(5-chloro-2-pyridinyl)-2-[(4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)





RN 267891-32-7 USPATFULL
CN Benzamide, N-3-pyridinyl-2-[(4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)





RN 267891-33-8 USPATFULL
CN Benzamide, 2-[(4-pyridinylmethyl)amino]-N-[5-(trifluoromethyl)-1,3,4-thiadiazol-2-yl]- (9CI) (CA INDEX NAME)



RN 267891-34-9 USPATFULL
CN Benzamide, 2-[(4-pyridinylmethyl)amino]-N-[[4-(trifluoromethyl)phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 267891-35-0 USPATFULL
CN Benzamide, N-(5-phenyl-1H-pyrazol-3-yl)-2-[(4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)



RN 267891-36-1 USPATFULL
CN Benzamide, N-(trans-4-phenylcyclohexyl)-2-[(4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 267891-37-2 USPATFULL
CN Benzamide, N-(1-isoquinolinylmethyl)-2-[(4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)



RN 267891-38-3 USPATFULL
CN Benzamide, 2-[(4-pyridinylmethyl)amino]-N-(2-quinolinylmethyl)- (9CI) (CA INDEX NAME)



RN 267891-39-4 USPATFULL
CN Benzamide, 2-[(4-pyridinylmethyl)amino]-N-(1,2,3,4-tetrahydro-7-quinolinyl)- (9CI) (CA INDEX NAME)



RN 267891-40-7 USPATFULL
CN Benzamide, N-(2-phenylcyclohexyl)-2-[(4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)



RN 267891-41-8 USPATFULL
CN Benzamide, N-(2,3-dihydro-1,4-benzodioxin-6-yl)-2-[(4-

pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)



RN 267891-42-9 USPATFULL
CN Benzamide, 2-[(4-pyridinylmethyl)amino]-N-6-quinolinyl- (9CI) (CA INDEX NAME)



RN 267891-43-0 USPATFULL
CN Benzamide, 2-[(4-pyridinylmethyl)amino]-N-2-quinolinyl- (9CI) (CA INDEX NAME)



RN 267891-44-1 USPATFULL
CN Benzamide, N-3-isoquinolinyl-2-[(4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)



RN 267891-45-2 USPATFULL
CN Benzamide, N-1H-indol-5-yl-2-[(4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)



RN 267891-46-3 USPATFULL
CN Benzamide, N-(3-methyl-2-quinolinyl)-2-[(4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)



RN 267891-47-4 USPATFULL
CN Benzamide, N-(6-chloro-3-methyl-2-quinolinyl)-2-[(4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)



RN 267891-48-5 USPATFULL
CN Benzamide, N-(7-chloro-3-methyl-2-quinolinyl)-2-[(4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)



RN 267891-49-6 USPATFULL
CN Benzamide, N-(6-fluoro-3-methyl-2-quinolinyl)-2-[(4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)



RN 267891-50-9 USPATFULL
CN Benzamide, N-(7-fluoro-3-methyl-2-quinolinyl)-2-[(4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)



RN 267891-51-0 USPATFULL
CN Benzamide, N-(6-methoxy-3-methyl-2-quinolinyl)-2-[(4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)



RN 267891-52-1 USPATFULL
CN Benzamide, N-(7-methoxy-3-methyl-2-quinolinyl)-2-[(4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)



RN 267891-53-2 USPATFULL
CN Benzamide, N-(5-chloro-2-quinazolinyl)-2-[(4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)



RN 267891-54-3 USPATFULL
CN Benzamide, 2-chloro-N-[(4-chlorophenyl)methyl]-6-[(4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)



RN 267891-55-4 USPATFULL
CN Benzamide, 2-chloro-6-[(4-pyridinylmethyl)amino]-N-2-quinolinyl- (9CI) (CA INDEX NAME)



RN 267891-56-5 USPATFULL
CN Benzamide, 5-chloro-2-[(4-pyridinylmethyl)amino]-N-2-quinolinyl- (9CI) (CA INDEX NAME)



RN 267891-57-6 USPATFULL
CN Benzamide, 4-fluoro-N-3-isoquinolinyl-2-[(4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)



RN 267891-58-7 USPATFULL
CN Benzamide, 4-chloro-2-[(4-pyridinylmethyl)amino]-N-2-quinolinyl- (9CI) (CA INDEX NAME)



RN 267891-59-8 USPATFULL
CN Benzamide, 4,5-difluoro-N-3-isoquinolinyl-2-[(4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)



RN 267891-61-2 USPATFULL
CN Benzamide, N-[(4-methoxyphenyl)methyl]-2-[[(4-methoxyphenyl)methyl]amino]- (9CI) (CA INDEX NAME)



RN 267891-63-4 USPATFULL
CN Benzamide, N-[2-(4-chlorophenyl)ethyl]-2-[[(4-hydroxyphenyl)methyl]amino]- (9CI) (CA INDEX NAME)



RN 267891-64-5 USPATFULL
CN Benzamide, 2-[[(1,6-dihydro-6-oxo-3-pyridinyl)methyl]amino]-N-3-isoquinolinyl- (9CI) (CA INDEX NAME)



RN 267891-65-6 USPATFULL
CN Benzamide, N-3-isoquinolinyl-2-[(4-pyrimidinylmethyl)amino]- (9CI) (CA INDEX NAME)



RN 267891-66-7 USPATFULL
CN Benzamide, 5-fluoro-N-3-isoquinolinyl-2-[(4-pyrimidinylmethyl)amino]- (9CI) (CA INDEX NAME)



RN 267891-67-8 USPATFULL
CN Benzamide, 4-fluoro-N-1H-indazol-5-yl-2-[(4-pyrimidinylmethyl)amino]- (9CI) (CA INDEX NAME)



RN 267891-68-9 USPATFULL
CN Benzamide, N-1H-indazol-5-yl-2-[(4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)



RN 267891-69-0 USPATFULL
CN Benzamide, N-1H-benzimidazol-2-yl-2-[(4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)



RN 267891-70-3 USPATFULL
CN Benzamide, N-6-benzothiazolyl-5-fluoro-2-[(4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)



RN 267891-72-5 USPATFULL
CN Benzamide, N-(5,6-dimethyl-1H-benzimidazol-2-yl)-2-[(4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)



RN 267891-73-6 USPATFULL
CN Benzamide, N-6-benzothiazolyl-2-[(4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)



RN 267891-74-7 USPATFULL
CN Benzamide, 2-[(4-pyridinylmethyl)amino]-N-[6-(trifluoromethoxy)-2-benzothiazolyl]- (9CI) (CA INDEX NAME)



RN 267891-75-8 USPATFULL
CN Benzamide, N-1H-indazol-6-yl-2-[(4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)



RN 267891-76-9 USPATFULL
CN Benzamide, N-4-pyridinyl-2-[(4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)



RN 267891-77-0 USPATFULL
CN Benzamide, N-(1-methyl-1H-benzimidazol-2-yl)-2-[(4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)



RN 267891-78-1 USPATFULL
CN Benzamide, N-(6-chloro-2-benzothiazolyl)-2-[(4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)



RN 267891-79-2 USPATFULL
CN Benzamide, N-1H-benzimidazol-5-yl-2-[(4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)



RN 267891-80-5 USPATFULL
CN Benzamide, N-(6-fluoro-2-benzothiazolyl)-2-[(4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)



RN 267891-81-6 USPATFULL
CN Benzamide, N-2-benzothiazolyl-5-chloro-2-[(4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)



RN 267891-82-7 USPATFULL
CN Benzamide, 5-fluoro-N-1H-indazol-5-yl-2-[(4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)



RN 267891-83-8 USPATFULL
CN Benzamide, 5-chloro-N-1H-indazol-5-yl-2-[(4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)



RN 267891-84-9 USPATFULL
CN Benzamide, N-2-benzothiazolyl-5-fluoro-2-[(4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)



RN 267891-85-0 USPATFULL
CN Benzamide, N-6-benzothiazolyl-5-chloro-2-[(4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)



IT **267891-92-9 267891-93-0 267891-94-1**
267891-95-2 267891-96-3 267891-97-4
267891-98-5 267891-99-6 267892-01-3
267892-02-4 267892-03-5 267892-04-6
267892-05-7 267892-06-8 267892-07-9
267892-09-1 267892-11-5 267892-14-8
267892-15-9
(prepn. of anthranilic acid amides as VEGF receptor inhibitors)

RN 267891-92-9 USPATFULL
CN Benzamide, N-(4-pyridinylmethyl)-2-[(4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)



RN 267891-93-0 USPATFULL
CN Benzamide, N-[3-(4-chlorophenyl)propyl]-2-[(4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)



RN 267891-94-1 USPATFULL

CN Benzamide, N-[2-(4-chlorophenyl)propyl]-2-[(4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)



RN 267891-95-2 USPATFULL
CN Benzamide, N-(2-phenylpropyl)-2-[(4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)



RN 267891-96-3 USPATFULL
CN Benzamide, N-(5-chloro-2,3-dihydro-1H-inden-1-yl)-2-[(4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)



RN 267891-97-4 USPATFULL
CN Benzamide, N-[2-(3,4-dimethoxyphenyl)ethyl]-2-[(4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)



RN 267891-98-5 USPATFULL
CN Benzamide, N-2,1,3-benzothiadiazol-5-yl-2-[(4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)



RN 267891-99-6 USPATFULL
CN Benzamide, 2-[(4-pyridinylmethyl)amino]-N-[(1R)-1,2,3,4-tetrahydro-1-naphthalenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 267892-01-3 USPATFULL
CN Benzamide, N-(4-phenylbutyl)-2-[(4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)



RN 267892-02-4 USPATFULL
CN Benzamide, 2-[(4-pyridinylmethyl)amino]-N-[(1S)-1,2,3,4-tetrahydro-1-naphthalenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 267892-03-5 USPATFULL
CN Benzamide, N-(2-phenylethyl)-2-[(4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)



RN 267892-04-6 USPATFULL
CN Benzamide, N-5-isoquinolinyl-2-[(4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)



RN 267892-05-7 USPATFULL
CN Benzamide, N-methyl-N-(2-phenylethyl)-2-[(4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)



RN 267892-06-8 USPATFULL
CN Benzamide, 5-chloro-N-[(4-chlorophenyl)methyl]-2-[(4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)



RN 267892-07-9 USPATFULL
CN Benzamide, 5-chloro-N-(3-phenylpropyl)-2-[(4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)



RN 267892-09-1 USPATFULL
CN Benzamide, 5-fluoro-N-3-isoquinolinyl-2-[(4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)



RN 267892-11-5 USPATFULL
CN Benzamide, 5-chloro-N-3-isoquinolinyl-2-[(4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)



RN 267892-14-8 USPATFULL
CN Benzamide, N-2-benzothiazolyl-4-fluoro-2-[(4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)



RN 267892-15-9 USPATFULL
CN Benzamide, N-(4-chloro-2-benzothiazolyl)-2-[(4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)



IT **267891-90-7**
(prepn. of anthranilic acid amides as VEGF receptor inhibitors)
RN 267891-90-7 USPATFULL
CN Benzamide, 2-[[(1,2-dihydro-2-oxo-4-pyridinyl)methyl]amino]-N-3-isoquinolinyl- (9CI) (CA INDEX NAME)



L31 ANSWER 51 OF 55 USPATFULL on STN
ACCESSION NUMBER: 2002:340339 USPATFULL
TITLE: Ortho-anthranilamide derivatives as anti-coagulants

INVENTOR(S): Arnaiz, Damian O., Hercules, CA, United States
Chou, Yuo-Ling, Lafayette, CA, United States
Griedel, Brian D., El Cerrito, CA, United States
Karanjawala, Rushad E., Hercules, CA, United States
Kochanny, Monica J., San Rafael, CA, United States
Lee, Wheeseong, Lafayette, CA, United States
Liang, Amy Mei, Richmond, CA, United States
Morrissey, Michael M., Danville, CA, United States
Phillips, Gary B., Pleasant Hill, CA, United States
Sacchi, Karna Lyn, San Francisco, CA, United States
Sakata, Steven T., San Diego, CA, United States
Shaw, Kenneth J., San Rafael, CA, United States
Snider, R. Michael, Napa, CA, United States
Wu, Shung C., Princeton, NJ, United States
Ye, Bin, Richmond, CA, United States
Zhao, Zuchun, El Sobrante, CA, United States

PATENT ASSIGNEE(S): Berlex Laboratories, Inc., Richmond, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6498185	B1	20021224
APPLICATION INFO.:	US 2000-631452		20000803 (9)

RELATED APPLN. INFO.: Division of Ser. No. US 1998-187459, filed on 5 Nov 1998, now patented, Pat. No. US 6140351
Continuation-in-part of Ser. No. US 1997-994284, filed on 19 Dec 1997, now abandoned

DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Seaman, D. Margaret
LEGAL REPRESENTATIVE: Roth, Carol J.
NUMBER OF CLAIMS: 17
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 0 Drawing Figure(s); 0 Drawing Page(s)
LINE COUNT: 10979
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention is directed to compounds of formula (III): ##STR1##

wherein B, C, D, E, R.sup.1, R.sup.2 and R.sup.3 are disclosed herein. These compounds are disclosed as being useful as anti coagulants.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT **229339-81-5P**
(prepn. of heteroarylcarbonylaminobenzamides and related compds. as anticoagulants)

RN 229339-81-5 USPATFULL

CN Benzamide, N-(4-chlorophenyl)-2-[[(3-methylbenzo[b]thien-2-yl)methyl]amino]- (9CI) (CA INDEX NAME)



L31 ANSWER 52 OF 55 USPATFULL on STN
ACCESSION NUMBER: 2002:102529 USPATFULL
TITLE: Anthranilic acid derivatives as inhibitors of the cGMP-phosphodiesterase
INVENTOR(S): Oku, Teruo, late of Tokyo, JAPAN deceasedess,ess, Tomohito Oku, United States heir
Sawada, Kozo, Tsukuba, JAPAN
Kuroda, Akio, Tsukuba, JAPAN
Inoue, Takayuki, Tsukuba, JAPAN
Kayakiri, Natsuko, Suita, JAPAN
Sawada, Yuki, Ushiku, JAPAN
Mizutani, Tsuyoshi, Tsukuba, JAPAN
PATENT ASSIGNEE(S): Fujisawa Pharmaceutical Co., Ltd., Osaka, JAPAN (non-U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 6384080	B1	20020507	
	WO 9954284		19991028	
APPLICATION INFO.:	US 2001-509541		20010423	(9)
	WO 1999-JP2028		19990415	
			20010423	PCT 371 date

	NUMBER	DATE
PRIORITY INFORMATION:	AU 1998-3085	19980420
	AU 1998-5851	19980911
	AU 1998-7781	19981218

DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Owens, Amelia
LEGAL REPRESENTATIVE: Oblon, Spivak, McClelland, Maier & Neustadt, P.C.
NUMBER OF CLAIMS: 6
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 0 Drawing Figure(s); 0 Drawing Page(s)
LINE COUNT: 5428
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Compounds of formula (I) ##STR1##

where R.sup.1 is hydrogen; R.sup.2 is nitro, cyano or halo(lower)alkyl; R.sup.3 is phenyl substituted with one or more substituents selected from halogen, cyano and lower alkoxy; A is a lower alkylene group; R.sup.4 is a group CR.sup.6R.sup.7R.sup.8 wherein R.sup.6 and R.sup.7 form, together with the carbon atom to which they are attached a cycloalkyl group optionally substituted with hydroxy, lower alkoxy or a lower alkanoylamino; and R.sup.8 is hydrogen; its prodrug and a salt thereof.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT **247569-27-3P 247570-30-5P**
(prepn. of anthranilamides as of cGMP-phosphodiesterase inhibitors)
RN 247569-27-3 USPATFULL
CN Benzamide, 5-cyano-N-[(3,4-dimethoxyphenyl)methyl]-2-[[(1S)-2-(1H-imidazol-1-yl)-1-methylethyl]amino]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 247570-30-5 USPATFULL
CN Benzamide, 5-cyano-N-[(3,4-dimethoxyphenyl)methyl]-2-[[(1S)-1-methyl-2-(2-methyl-1H-imidazol-1-yl)ethyl]amino]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

L31 ANSWER 53 OF 55 USPATFULL on STN
ACCESSION NUMBER: 2002:95814 USPATFULL
TITLE: Ortho-anthranilamide derivatives as anti-coagulants
INVENTOR(S): Arnaiz, Damian O., Hercules, CA, United States
Chou, Yuo-Ling, Lafayette, CA, United States
Griedel, Brian D., El Cerrito, CA, United States
Karanjawala, Rushad E., Hercules, CA, United States
Kochanny, Monica J., San Rafael, CA, United States
Lee, Wheeseong, Lafayette, CA, United States
Liang, Amy Mei, Richmond, CA, United States
Morrissey, Michael M., Danville, CA, United States
Phillips, Gary B., Pleasant Hill, CA, United States
Sacchi, Karna Lyn, San Francisco, CA, United States

Sakata, Steven T., San Diego, CA, United States
Shaw, Kenneth J., San Rafael, CA, United States
Snider, R. Michael, Napa, CA, United States
Wu, Shung C., Princeton, NJ, United States
Ye, Bin, Richmond, CA, United States
Zhao, Zuchun, El Sobrante, CA, United States
PATENT ASSIGNEE(S): Berlex Laboratories, Inc., Richmond, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6380221	B1	20020430
APPLICATION INFO.:	US 2000-631450		20000803 (9)

RELATED APPLN. INFO.: Division of Ser. No. US 1998-187459, filed on 5 Nov 1998, now patented, Pat. No. US 6140351
Continuation-in-part of Ser. No. US 1997-994284, filed on 19 Dec 1997, now abandoned
DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Seaman, D. Margaret
LEGAL REPRESENTATIVE: Roth, Carol J.
NUMBER OF CLAIMS: 5
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 0 Drawing Figure(s); 0 Drawing Page(s)
LINE COUNT: 10754
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB This invention is directed to compounds of formula (III): ##STR1##

wherein B, C, D, E, R.sup.1, R.sup.2 and R.sup.3 are disclosed herein. These components are disclosed as being useful as anti-coagulants.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT **229339-81-5P**
(prepn. of heteroarylcarbonylaminobenzamides and related compds. as anticoagulants)
RN 229339-81-5 USPATFULL
CN Benzamide, N-(4-chlorophenyl)-2-[[(3-methylbenzo[b]thien-2-yl)methyl]amino]- (9CI) (CA INDEX NAME)



L31 ANSWER 54 OF 55 USPATFULL on STN
ACCESSION NUMBER: 1998:14840 USPATFULL
TITLE: Anthranilic acid derivatives
INVENTOR(S): Ozaki, Fumihiro, Ibaraki, Japan
Ishibashi, Keiji, Ibaraki, Japan
Ikuta, Hironori, Ibaraki, Japan
Ishihara, Hiroki, Ibaraki, Japan
Souda, Shigeru, Ibaraki, Japan
PATENT ASSIGNEE(S): Eisai Co., Ltd., Japan (non-U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 5716993		19980210	
	WO 9518097		19950706	
APPLICATION INFO.:	US 1995-507476		19950914	(8)
	WO 1994-JP2262		19941227	
			19950916	PCT 371 date
			19950916	PCT 102(e) date

	NUMBER	DATE
PRIORITY INFORMATION:	JP 1993-347092	19931227
	JP 1994-299110	19941009

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Owens, Amelia
LEGAL REPRESENTATIVE: Nixon & Vanderhye
NUMBER OF CLAIMS: 7
EXEMPLARY CLAIM: 1
LINE COUNT: 3902
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides an anthranilic acid derivative having a cGMP-PDE inhibitory activity.

An anthranilic acid derivative represented by the general formula (I) or a pharmacologically acceptable salt thereof: ##STR1## [wherein R.sup.1, R.sup.2, R.sup.3 and R.sup.4 represent the same or different from each other, a hydrogen atom, a halogen atom, a hydroxy group, an optionally halogenated lower alkyl group, an optionally halogenated lower alkoxy group, a nitro group, a hydroxyalkyl group, a cyano group or the like; R.sup.5 and R.sup.6 represent the same or different from each other, a hydrogen atom, a halogen atom, a hydroxy group, a cyano group, an optionally halogenated lower alkyl group, an optionally halogenated lower alkoxy group or the like;

W represents a group of the formula: --N.dbd. or --CH.dbd.; R.sup.7 and R.sup.8 represent the same or different from each other, a hydrogen atom, an optionally halogenated lower alkyl group or the like;

A represents a hydrogen atom, an optionally halogenated lower alkyl group or the like;

Y represents an oxygen atom or a sulfur atom; and

n is an integer of 0 to 6].

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT **169043-60-1P**
(prepn. of anthranilamide derivs. as cyclic guanosine monophosphate-phosphodiesterase inhibitors)
RN 169043-60-1 USPATFULL
CN Benzamide, N-(1,3-benzodioxol-5-ylmethyl)-5-chloro-2-[(4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)



L31 ANSWER 55 OF 55 USPATFULL on STN
ACCESSION NUMBER: 86:6642 USPATFULL
TITLE: N-[2-4-(1H-Imidazol-1-yl)alkyl]-arylamides and pharmaceutical compositions
INVENTOR(S): Wright, Jr., William B., Woodcliff Lake, NJ, United States
Press, Jeffrey B., Tuxedo, NY, United States
PATENT ASSIGNEE(S): American Cyanamid Company, Stamford, CT, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 4568687		19860204
APPLICATION INFO.:	US 1984-570160		19840113 (6)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1983-470112, filed on 28 Feb 1983, now abandoned
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Ramsuer, Robert W.
LEGAL REPRESENTATIVE: Conroy, Jr., Edward A.
NUMBER OF CLAIMS: 15
EXEMPLARY CLAIM: 1,15
LINE COUNT: 1330
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB This disclosure describes novel N-[.omega.-(1H-imidazol-1-yl)alkyl]arylamides which possess the property of inhibiting the enzyme thromboxane synthetase and are also useful in the treatment of hypertension and myocardial ischemia.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT **93668-03-2P**
(prepn., antihypertensive, and platelet aggregation inhibiting activity of)
RN 93668-03-2 USPATFULL
CN Benzamide, N-[3-(1H-imidazol-1-yl)propyl]-2-[(phenylmethyl)amino]- (9CI) (CA INDEX NAME)



FILE 'CAOLD' ENTERED AT 15:18:55 ON 16 MAR 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907-1966
FILE LAST UPDATED: 01 May 1997 (19970501/UP)

This file contains CAS Registry Numbers for easy and accurate substance identification. Title keywords, authors, patent assignees, and patent information, e.g., patent numbers, are now searchable from 1907-1966. TIFF images of CA abstracts printed between 1907-1966 are available in the PAGE display formats.

This file supports REG1stRY for direct browsing and searching of all substance data from the REGISTRY file. Enter HELP FIRST for more information.

```
L16             STR
L18             STR
L21         425 SEA FILE=REGISTRY SSS FUL L16 NOT L18
L25             STR
L27         325 SEA FILE=REGISTRY SUB=L21 SSS FUL L25
L30           2 SEA FILE=CAOLD ABB=ON  L27
```

=> d iall hitstr l30 1-2

L30 ANSWER 1 OF 2 CAOLD COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: CA64:8153f CAOLD
TITLE: pyridylethylated anthranilamides
AUTHOR NAME: Schipper, Edgar
PATENT ASSIGNEE: Shulton, Inc.
DOCUMENT TYPE: Patent

PATENT NO.	KIND	DATE
US 3226394		1965

INDEX TERM:

2385-25-3	4943-68-4	4943-69-5	4943-70-8	4943-71-9
4943-72-0	4943-73-1	4943-74-2	4943-75-3	
4943-76-4	4943-77-5	4943-78-6	4943-79-7	
4943-80-0	4943-81-1	4943-82-2	4943-83-3	4943-85-5

4943-86-6 **4959-58-4** **4959-59-5**
4959-60-8 **5004-85-3** 5004-86-4 5004-87-5

IT **4943-76-4** **4959-58-4** **4959-59-5**
5004-85-3

RN 4943-76-4 CAOLD
CN Benzanilide, 4'-chloro-2-[[2-(4-pyridyl)ethyl]amino]- (7CI, 8CI) (CA INDEX NAME)





RN 4959-58-4 CAOLD
CN Benzamide, 5-chloro-N-(3,4,-dimethoxyphenethyl)-2-[[2-(4-pyridyl)ethyl]amino]- (7CI, 8CI) (CA INDEX NAME)



RN 4959-59-5 CAOLD
CN o-Benzotoluidide, 2-[[2-(4-pyridyl)ethyl]amino]- (7CI, 8CI) (CA INDEX NAME)





RN 5004-85-3 CAOLD
CN p-Benzanisidide, 5-chloro-2-[[2-(4-pyridyl)ethyl]amino]- (7CI, 8CI) (CA INDEX NAME)





L30 ANSWER 2 OF 2 CAOLD COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: CA55:11421a CAOLD
TITLE: reaction of halopyruvic acid with thiolamines
AUTHOR NAME: Hermann, Peter
INDEX TERM: 1769-25-1 1772-97-0 2385-23-1 2436-66-0 4260-34-8
5388-11-4 19857-37-5 22316-59-2 22686-82-4 24122-33-6
50677-59-3 53628-24-3 74375-17-0 **85094-67-3**
102542-99-4 109309-98-0 109310-83-0 109730-50-9 109814-09-7
110491-88-8 110936-49-7 110936-58-8 112600-79-0 114986-35-5
IT **85094-67-3**
RN 85094-67-3 CAOLD
CN Benzamide, 2-[[(4-methoxyphenyl)thioxomethyl]amino]-N-(phenylmethyl)-
(9CI) (CA INDEX NAME)



=> fil hom
FILE 'HOME' ENTERED AT 15:19:12 ON 16 MAR 2004